Publicaties van Richard Bruggeman

Association between cognitive phenotype in unaffected siblings and prospective 3- and 6-year clinical outcome in their proband affected by psychosis. Burger TJ, Schirmbeck F, Vermeulen JM, Quee PJ, de Koning MB, Bruggeman R, de Haan L, van Amelsvoort T, Bartels-Velthuis AA, Bruggeman R, Cahn W, de Haan L, Schirmbeck F, Simons CJP, van Os J.Psychol Med. 2020 Apr 15:1-11. [doi: 10.1017/S0033291720000719].

Expressive deficits and amotivation as mediators of the associations between cognitive problems and functional outcomes: Results from two independent cohorts. Liemburg EJ, Enriquez-Geppert S, Wardenaar KJ, Bruggeman R, Aleman A; PROGR-S investigators; GROUP investigators.Schizophr Res. 2020 Apr;218:283-291. [doi: 10.1016/j.schres.2019.12.018].

Bos FM, Snippe E, Bruggeman R, Wichers M, Krieke van der L. (2019). Insights of Patients and Clinicians on the Promise of the Experience Sampling Method for Psychiatric Care. Psychiatric services, appips201900050. [Volledige tekst]

Fuermaier ABM, Piersma D, Huntjens RJC, Waard de D, Westermann C, Bossert M, Lange KW, Weisbrod M, Bruggeman R, Aschenbrenner S, Tucha O. (2019). Simulated car driving and its association with cognitive abilities in patients with schizophrenia. Schizophrenia research, 204: 171-177. [Volledige tekst]

Habtewold T, Bruggeman R, Liemburg EJ, Islam MA, Alizadeh BZ. (2019). Type 2 diabetes mellitus in patients with schizophrenia: the effect of (poly)genetic risk score of schizophrenia and type 2 diabetes and antipsychotic medication use. European Neuropsychopharmacology, 29: S1335. [Abstract]

Knegtering H, Bruggeman R (2019). Farmacotherapie (van psychotische stoornissen). In: Cahn W, Mynin-Germeys I, Bruggeman R, Haan de L (eds). Handboek schozofreniespectrum-stoornissen, tweede druk. Amsterdam: Boom Uitgevers Amsterdam, 611-633[Inhoudsopgave]

Knegtering H, Bruggeman R (2019). Farmacotherapie in de praktijk. In: Cahn W, Mynin-Germeys I, Bruggeman R, Haan de L (eds). Handboek schizofreniespectrum-stoornissen, tweede druk. Amsterdam: Boom Uitgevers Amsterdam, 633-657[Inhoudsopgave]

Knegtering H, Nienhuis F (2019). De differentiaal diagnostiek (van psychotische stoornissen). In: Cahn W, Mynin-Germeys I, Bruggeman R, Haan de L (eds). Handboek schizofreniespectrum-stoornissen, tweede druk. Amsterdam: Boom Uitgevers Amsterdam, 107-127[Inhoudsopgave]

Konings S, Bruggeman R, Mierau JO, Feenstra T, Visser E, Schoevers RA. (2019). Personalized healthcare episode identification in schizophrenia spectrum disorder using healthcare consumption trajectories. Value in Health, 22: S689. [Abstract]

Looijmans A, Jorg F, Bruggeman R, Schoevers RA, Corpeleijn E. (2019). Multimodal lifestyle intervention using a web-based tool to improve cardiometabolic health in patients with serious mental illness: results of a cluster randomized controlled trial (LION). BMC psychiatry, 19: 339-019-2310-5. [Volledige tekst]

Moolen van der AEGM, Slooff C, Bruggeman R, Knegtering H (2019). Psycho-educatie. In: Cahn W, Mynin-Germeys IB,R., Haan de L (eds). Handboek schizofreniespectrum-stoornissen, tweede druk. Amsterdam: Boom Uitgevers Amsterdam, 679-799[Inhoudsopgave]

Nienhuis F, Knegtering H (2019). Classificatie van psychotische stoornissen. In: Cahn W, Mynin-Germeys I, Bruggeman R, Haan de L (eds). Handboek schizofreniespectrum-stoornissen, tweede druk. Amsterdam: Boom Uitgevers Amsterdam, 75-107[Inhoudsopgave]

Ommen van MM, Laar van T, Cornelissen FW, Bruggeman R. (2019). Visual hallucinations in psychosis. Psychiatry research, 280: 112517. [Volledige tekst]

Roebroek LO, Bruins J, Knegtering H, Bruggeman R, Delespaul PH, Castelein S. (2019). Decision aid for the treatment of psychotic illness: development of TReatment E-AssisT (TREAT). Tijdschrift voor psychiatrie, 61: 92-96. [Volledige tekst]

Rooijen van G, Rooijen van M, Maat A, Vermeulen JM, Meijer CJ, Ruhe HG, Haan de L, GROUP investigators, Genetic Risk and Outcome of Psychosis investigators:, Alizadeh BZ, Bartels-Velthuis AA, Beveren van NJ, Bruggeman R, Cahn W, Delespaul P, Myin-Germeys I, Kahn RS, Schirmbeck F, Simons CJP, Amelsvoort van T, Haren van NE, Os van J, Winkel van R. (2019). Longitudinal evidence for a relation between depressive symptoms and quality of life in schizophrenia using structural equation modeling. Schizophrenia research, 208: 82-89. [Volledige tekst]

Simoons M, Mulder H, Doornbos B, Raats PCC, Bruggeman R, Cath DC, Schoevers RA, Ruhe HG, Roon van EN. (2019). Metabolic Syndrome at an Outpatient Clinic for Bipolar Disorders: A Case for Systematic Somatic Monitoring. Psychiatric services, 70: 143-146. [Volledige tekst]

Simoons M, Ruhe HG, Roon van EN, Schoevers RA, Bruggeman R, Cath DC, Muis D, Arends J, Doornbos B, Mulder H. (2019). Design and methods of the ‘monitoring outcomes of psychiatric pharmacotherapy’ (MOPHAR) monitoring program – a study protocol. BMC health services research, 19: 125. [Volledige tekst]

Stiekema APM, Islam MA, Liemburg EJ, Castelein S, Heuvel van den ER, Weeghel van J, Aleman A, Bruggeman R, Meer van der L, GROUP investigators, Alizadeh BZ, Bartels-Velthuis AA, Beveren van NJ, Bruggeman R, Cahn W, Haan de L, Delespaul P, Meijer CJ, Myin-Germeys I, Kahn RS, Schirmbeck F, Simons CJP, Haren van NEM, Os van J, Winkel van R. (2019). Corrigendum to “Long-term course of negative symptom subdomains and relationship with outcome in patients with a psychotic disorder” [Schizophr. Res. 193 (2018) 173-181]. Schizophrenia research, 204: 462-463. [Volledige tekst]

Swets M, Dijk van FA, Schirmbeck F, Peen J, Haan de L, Alizadeh BZ, Amelsvoort van T, Bartels-Velthuis AA, Beveren van NJ, Bruggeman R, Cahn W, Delespaul P, Luykx JJ, Myin-Germeys I, Kahn RS, Simons CJP, Haren van NE, Os van J, Winkel van R. (2019). Patterns of obsessive-compulsive symptoms and social functioning in schizophrenia; a replication study. Psychiatry research, 271: 421-427. [Volledige tekst]

Vries de B, Pijnenborg GHM, Stouwe van der ECD, Visser E, Jong de S, Pharmaco therapy and outcome survey (PHAMOUS)-investigators, Bartels-Velthuis AA, Bruggeman R, Castelein S, Jorg F, Veling W, Aleman A, Busschbach van JT. (2019). “Please tell me what happened”: A descriptive study on prevalence, disclosure and characteristics of victimization in people with a psychotic disorder. PloS one, 14: e0219056. [Volledige tekst]

Bartels-Velthuis AA, Visser E, Arends J, Pijnenborg GHM, Wunderink L, Jorg F, Veling W, Liemburg EJ, Castelein S, Knegtering H, Bruggeman R. (2018). Towards a comprehensive routine outcome monitoring program for people with psychotic disorders: The Pharmacotherapy Monitoring and Outcome Survey (PHAMOUS). Schizophrenia Research, 197: 281-287. [Volledige tekst]

Bruins J, Jorg F, Heuvel van den ER, Bartels-Velthuis AA, Corpeleijn E, Muskiet FAJ, Pijnenborg GHM, Bruggeman R. (2018). The relation of vitamin D, metabolic risk and negative symptom severity in people with psychotic disorders. Schizophrenia research, 195: 513-518. [Volledige tekst]

Hoenders HJR, Bartels-Velthuis AA, Vollbehr NK, Bruggeman R, Knegtering H, Jong de JTVM. (2018). Natural Medicines for Psychotic Disorders: A Systematic Review. Journal of Nervous and Mental Disease, 206: 81-101. [Volledige tekst]

Islam MA, Habtewold TD, Es vD, Quee PJ, Heuvel van den ER, Alizadeh BZ, Bruggeman R, GROUP Investigators. (2018). Long-term cognitive trajectories and heterogeneity in patients with schizophrenia and their unaffected siblings. Acta Psychiatrica Scandinavica, 138: 591-604. [Volledige tekst]

Knegtering R ,Bruggeman R (2018). 6.1 Psychofarmacologie, van een historisch perspectief tot hedendaagse toepassing. In: Bak M, Domen P ,Os van J (eds). Innovatief leerboek persoonlijke psychiatrie. Houten: Bohn Stafleu van Loghum, 191-208

Mansueto G, Nierop van M, Schruers K, GROUP Investigators, Alizadeh BZ, Bartels-Velthuis AA, Beveren van NJ, Bruggeman R, Cahn W, Haan de L, Delespaul P, Meijer CJ, Myin-Germeys I, Kahn RS, Schirmbeck F, Simons CJP, Haren van NEM, Os van J, Winkel van R. (2018). The role of cognitive functioning in the relationship between childhood trauma and a mixed phenotype of affective-anxious-psychotic symptoms in psychotic disorders. Schizophrenia research, 192: 262-268. [Volledige tekst]

Nijs de J, Meijer JH, Haan de L, Meijer CJ, Bruggeman R, Haren van NEM, Kahn RS, Cahn W. (2018). Associations between olfactory identification and (social) cognitive functioning: A cross-sectional study in schizophrenia patients and healthy controls. Psychiatry research, 266: 147-151. [Volledige tekst]

Simoons M, Mulder H, Doornbos B, Raats PCC, Bruggeman R, Cath DC, Schoevers RA, Ruhe HG, Roon van EN. (2018). Metabolic Syndrome at an Outpatient Clinic for Bipolar Disorders: A Case for Systematic Somatic Monitoring. Psychiatric services, 70: 143-146. [Volledige tekst]

Stiekema APM, Islam MA, Liemburg EJ, Castelein S, Heuvel van den ER, Weeghel van J, Aleman A, Bruggeman R, Meer van der L, GROUP-investigators. (2018). Long-term course of negative symptom subdomains and relationship with outcome in patients with a psychotic disorder. Schizophrenia research, 193: 173-181. [Volledige tekst]

Stiekema APM, Looijmans A, Meer van der L, Bruggeman R, Schoevers RA, Corpeleijn E, Jorg F. (2018). Effects of a lifestyle intervention on psychosocial well-being of severe mentally ill residential patients: ELIPS, a cluster randomized controlled pragmatic trial. Schizophrenia research, 199: 407-413. [Volledige tekst]

Swets M, Dijk van FA, Schirmbeck F, Peen J, Haan de L, Alizadeh BZ, Amelsvoort van T, Bartels-Velthuis AA, Beveren van NJ, Bruggeman R, Cahn W, Delespaul P, Luykx JJ, Myin-Germeys I, Kahn RS, Simons CJP, Haren van NE, Os van J, Winkel van R. (2018). Patterns of obsessive-compulsive symptoms and social functioning in schizophrenia; a replication study. Psychiatry research, 271: 421-427. [Volledige tekst]

Swildens WE, Visser E, Bahler M, Bruggeman R, Delespaul P, Gaag van der M, Haan de L, Keet R, Nijssen Y, Os van J, Pijnenborg GM, Slooff C, Vos de A, Weeghel van J, Wunderink L, Mulder CL, Wiersma D. (2018). Functional recovery of individuals with serious mental illnesses: Development and testing of a new short instrument for routine outcome monitoring. Psychiatric rehabilitation journal, 41: 341-350. [Volledige tekst]

Veling W, Sommer IEC, Bruggeman R, Haan de L. (2018). Personalised medicine for psychosis. Tijdschrift voor Psychiatrie, 60: 161-165. [Volledige tekst]

Vermeulen JM, Schirmbeck F, Blankers M, Tricht van M, Bruggeman R, Brink van den W, Haan de L, Genetic Risk and Outcome of Psychosis (GROUP) Investigators. (2018). Association between smoking behavior and cognitive functioning in patients with psychosis, siblings, and healthy control subjects: results from a prospective 6-year follow-up study. American Journal of Psychiatry, 175: 1121-1128. [Volledige tekst]

Aleman A, Lincoln TM, Bruggeman R, Melle I, Arends J, Arango C, Knegtering H. (2017). Treatment of negative symptoms: Where do we stand, and where do we go? Schizophrenia Research, 186: 62. [Volledige tekst]

Looijmans A, Jorg F, Bruggeman R, Schoevers R, Corpeleijn E. (2017). Design of the Lifestyle Interventions for severe mentally ill Outpatients in the Netherlands (LION) trial; a cluster randomised controlled study of a multidimensional web tool intervention to improve cardiometabolic health in patients with severe mental illness. BMC Psychiatry, 17: 107-017-1265-7. [Volledige tekst]

Bais L, Liemburg E, Vercammen A, Bruggeman R, Knegtering R, Aleman A. (2017). Effects of low frequency rTMS treatment on brain networks for inner speech in patients with schizophrenia and auditory verbal hallucinations. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 78: 105-113. [Volledige tekst]

Bruins J, Pijnenborg GH, Heuvel van den ER, Visser E, Corpeleijn E, Bartels-Velthuis AA, Bruggeman R, Jorg F. (2017). Persistent Low Rates of Treatment of Metabolic Risk Factors in People With Psychotic Disorders: A PHAMOUS Study. Journal of Clinical Psychiatry, 78: 1117-1125. [Volledige tekst]

Islam MA, Hayat Khan MF, Quee PJ, Snieder H, Heuvel van den ER, Bruggeman R, Alizadeh BZ, Bartels-Velthuis AA, Beveren van NJ, Cahn W, Haan de L, Delespaul P, Meijer CJ, Myin-Germeys I, Kahn RS, Schirmbeck F, Simons CJP, Haren van NE, Os van J, Winkel van R. (2017). Familial liability to psychosis is a risk factor for multimorbidity in people with psychotic disorders and their unaffected siblings. European Psychiatry, 45: 81-89. [Volledige tekst]

Marshall CR, Howrigan DP, Merico D, Thiruvahindrapuram B, Wu W, Greer DS, Antaki D, Shetty A, Holmans PA, Pinto D, Gujral M, Brandler WM, Malhotra D, Wang Z, Fajarado KVF, Maile MS, Ripke S, Agartz I, Albus M, Alexander M, Amin F, Atkins J, Bacanu SA, Belliveau RA,Jr, Bergen SE, Bertalan M, Bevilacqua E, Bigdeli TB, Black DW, Bruggeman R, Buccola NG, Buckner RL, Bulik-Sullivan B, Byerley W, Cahn W, Cai G, Cairns MJ, Campion D, Cantor RM, Carr VJ, Carrera N, Catts SV, Chambert KD, Cheng W, Cloninger CR, Cohen D, Cormican P, Craddock N, Crespo-Facorro B, Crowley JJ, Curtis D, Davidson M, Davis KL, Degenhardt F, Del Favero J, DeLisi LE, Dikeos D, Dinan T, Djurovic S, Donohoe G, Drapeau E, Duan J, Dudbridge F, Eichhammer P, Eriksson J, Escott-Price V, Essioux L, Fanous AH, Farh KH, Farrell MS, Frank J, Franke L, Freedman R, Freimer NB, Friedman JI, Forstner AJ, Fromer M, Genovese G, Georgieva L, Gershon ES, Giegling I, Giusti-Rodriguez P, Godard S, Goldstein JI, Gratten J, Haan de L, Hamshere ML, Hansen M, Hansen T, Haroutunian V, Hartmann AM, Henskens FA, Herms S, Hirschhorn JN, Hoffmann P, Hofman A, Huang H, Ikeda M, Joa I, Kahler AK, Kahn RS, Kalaydjieva L, Karjalainen J, Kavanagh D, Keller MC, Kelly BJ, Kennedy JL, Kim Y, Knowles JA, Konte B, Laurent C, Lee P, Lee SH, Legge SE, Lerer B, Levy DL, Liang KY, Lieberman J, Lonnqvist J, Loughland CM, Magnusson PKE, Maher BS, Maier W, Mallet J, Mattheisen M, Mattingsdal M, McCarley RW, McDonald C, McIntosh AM, Meier S, Meijer CJ, Melle I, Mesholam-Gately RI, Metspalu A, Michie PT, Milani L, Milanova V, Mokrab Y, Morris DW, Muller-Myhsok B, Murphy KC, Murray RM, Myin-Germeys I, Nenadic I, Nertney DA, Nestadt G, Nicodemus KK, Nisenbaum L, Nordin A, O’Callaghan E, O’Dushlaine C, Oh SY, Olincy A, Olsen L, O’Neill FA, Os van J, Pantelis C, Papadimitriou GN, Parkhomenko E, Pato MT, Paunio T, Psychosis Endophenotypes International Consortium, Perkins DO, Pers TH, Pietilainen O, Pimm J, Pocklington AJ, Powell J, Price A, Pulver AE, Purcell SM, Quested D, Rasmussen HB, Reichenberg A, Reimers MA, Richards AL, Roffman JL, Roussos P, Ruderfer DM, Salomaa V, Sanders AR, Savitz A, Schall U, Schulze TG, Schwab SG, Scolnick EM, Scott RJ, Seidman LJ, Shi J, Silverman JM, Smoller JW, Soderman E, Spencer CCA, Stahl EA, Strengman E, Strohmaier J, Stroup TS, Suvisaari J, Svrakic DM, Szatkiewicz JP, Thirumalai S, Tooney PA, Veijola J, Visscher PM, Waddington J, Walsh D, Webb BT, Weiser M, Wildenauer DB, Williams NM, Williams S, Witt SH, Wolen AR, Wormley BK, Wray NR, Wu JQ, Zai CC, Adolfsson R, Andreassen OA, Blackwood DHR, Bramon E, Buxbaum JD, Cichon S, Collier DA, Corvin A, Daly MJ, Darvasi A, Domenici E, Esko T, Gejman PV, Gill M, Gurling H, Hultman CM, Iwata N, Jablensky AV, Jonsson EG, Kendler KS, Kirov G, Knight J, Levinson DF, Li QS, McCarroll SA, McQuillin A, Moran JL, Mowry BJ, Nothen MM, Ophoff RA, Owen MJ, Palotie A, Pato CN, Petryshen TL, Posthuma D, Rietschel M, Riley BP, Rujescu D, Sklar P, St Clair D, Walters JTR, Werge T, Sullivan PF, O’Donovan MC, Scherer SW, Neale BM, Sebat J, CNV and Schizophrenia Working Groups of the Psychiatric Genomics Consortium. (2017). Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nature Genetics, 49: 27-35. [Volledige tekst]

Looijmans A, Stiekema APM, Bruggeman R, Meer van der L, Stolk RP, Schoevers RA, Jorg F, Corpeleijn E. (2017). Changing the obesogenic environment to improve cardiometabolic health in residential patients with a severe mental illness: cluster randomised controlled trial. British Journal of Psychiatry, 211: 296-303. [Volledige tekst]

Pos K, Wit de IE, Dijk van FA, Bartels-Velthuis AA, Bruggeman R, Meijer CJ, Haan de L, for Group, Genetic Risk and Outcome of Psychosis investigators, Alizadeh BZ, Bartels-Velthuis AA, Beveren van NJ, Bruggeman R, Cahn W, Haan de L, Delespaul P, Meijer CJ, Myin-Germeys I, Kahn RS, Schirmbeck F, Simons CJP, Haren van NE, Os van J, Winkel van R. (2017). An experience sampling study on the ecological validity of the SWN-20: Indication that subjective well-being is associated with momentary affective states above and beyond psychosis susceptibility. Psychiatry research, 258: 234-238. [Volledige tekst]

Tasma M, Swart M, Wolters G, Liemburg EJ, Bruggeman R, Knegtering H, Castelein S. (2017). Clinical application of ROM in psychosis. Nederlands tijdschrift voor geneeskunde, 161: D944. [Volledige tekst]

Knegtering H, Bruggeman R. (2017). Psychofarmacologie, van een historische perspectief tot hedendaagse toepassing. GGzet Wetenschappelijk, 1: 72-80.

Tasma M, Swart M, Wolters G, Liemburg EJ, Bruggeman R, Knegtering H, Castelein S. (2017). Klinische toepassing van ROM bij psychose. GGzet Wetenschappelijk, 1: 95-102. [Volledige tekst]

Bartels-Velthuis AA, Wigman JT, Jenner JA, Bruggeman R, Os van J. (2016). Course of auditory vocal hallucinations in childhood: 11-year follow-up study. Acta Psychiatrica Scandinavica, 134: 6-15. [Volledige tekst]

Bruins J, Pijnenborg MG, Bartels-Velthuis AA, Visser E, Heuvel van den ER, Bruggeman R, Jorg F. (2016). Cannabis use in people with severe mental illness: The association with physical and mental health – a cohort study. A Pharmacotherapy Monitoring and Outcome Survey study. Journal of Psychopharmacology, 30: 354-362. [Volledige tekst]

Heering HD, Goedhart S, Bruggeman R, Cahn W, Haan de L, Kahn RS, Meijer CJ, Myin-Germeys I, Os van J, Wiersma D. (2016). Disturbed Experience of Self: Psychometric Analysis of the Self-Experience Lifetime Frequency Scale (SELF). Psychopathology, 49: 69-76. [Volledige tekst]

Lako IM, Taxis K, Heuvel van den ER, Leenaars CH, Burger H, Wiersma D, Slooff CJ, Knegtering H, Bruggeman R. (2016). Altered emotional experiences attributed to antipsychotic medications – A potential link with estimated dopamine D receptor occupancy. Psychiatry Research, 236: 9-14. [Volledige tekst]

Lokkerbol J, Nuijen J, Evers S, Knegtering H, Delespaul P, Kroon H, Bruggeman R. (2016). A study of cost-effectiveness of treating serious mental illness: challenges and solutions. Tijdschrift voor Psychiatrie, 58: 700-705. [Volledige tekst]

Medema S, Mocking RJ, Koeter MW, Vaz FM, Meijer C, Haan de L, Beveren van NJ, GROUP, Genetic Risk and Outcome of Psychosis investigators:, Kahn R, Haan de L, Os van J, Wiersma D, Bruggeman R, Cahn W, Meijer C, Myin-Germeys I. (2016). Levels of Red Blood Cell Fatty Acids in Patients With Psychosis, Their Unaffected Siblings, and Healthy Controls. Schizophrenia bulletin, 42: 358-368. [Volledige tekst]

Meijer JH, Harten van P, Meijer CJ, Koeter MW, Bruggeman R, Cahn W, Kahn RS, Haan de L, Genetic Risk and Outcome of Psychosis (GROUP) Study. (2016). Association between olfactory identification and parkinsonism in patients with non-affective psychosis. Early Intervention in Psychiatry, 10: 404-410. [Volledige tekst]

Peeters SC, Gronenschild EH, Amelsvoort van T, Os van J, Marcelis M, Genetic Risk and Outcome of Psychosis (G.R.O.U.P.), Kahn R, Wiersma D, Bruggeman R, Cahn W, Haan de L, Meijer C, Myin-Germeys I. (2016). Reduced specialized processing in psychotic disorder: a graph theoretical analysis of cerebral functional connectivity. Brain and Behavior, 6: e00508. [Volledige tekst]

Scholte-Stalenhoef AN, Bastide la-van Gemert S, Willige van de G, Dost-Otter R, Visser E, Liemburg EJ, Knegtering H, Heuvel van den ER, Schoevers RA, Pijnenborg GH, Bruggeman R. (2016). Personality and coping in first episode psychosis linked to mental health care use. Psychiatry Research, 238: 218-224. [Volledige tekst]

Smid HG, Bruggeman R, Martens S. (2016). Normal cognitive conflict resolution in psychosis patients with and without schizophrenia. Journal of Abnormal Psychology, 125: 88-103. [Volledige tekst]

Steenhuis LA, Bartels-Velthuis AA, Jenner JA, Aleman A, Bruggeman R, Nauta MH, Pijnenborg GH. (2016). Religiosity in young adolescents with auditory vocal hallucinations. Psychiatry Research, 236: 158-164. [Volledige tekst]

Stiekema AP, Liemburg EJ, Meer van der L, Castelein S, Stewart R, Weeghel van J, Aleman A, Bruggeman R. (2016). Confirmatory Factor Analysis and Differential Relationships of the Two Subdomains of Negative Symptoms in Chronically Ill Psychotic Patients. PloS One, 11: e0149785. [Volledige tekst]

Tasma M, Swart M, Wolters G, Liemburg E, Bruggeman R, Knegtering H, Castelein S. (2016). Do routine outcome monitoring results translate to clinical practice? A cross-sectional study in patients with a psychotic disorder. BMC Psychiatry, 16: 107. [Volledige tekst]

Agthoven van M, Kolk van der A, Knegtering H, Delespaul PA, Arends J, Jeurissen PP, Krabbe PF, Huijsman R, Luijk R, Beurs de E, Hakkaart-Van Roijen L, Bruggeman R. (2015). Cost-effectiveness in Dutch mental health care: future because of ROM? Tijdschrift voor Psychiatrie, 57: 672-679. [Volledige tekst]

Bruggeman R, Veling W, Es van F, Quak J, Nienhuis F, Knegtering R. (2015). The end of schizophrenia in the Netherlands? not yet. Tijdschrift voor Psychiatrie, 57: 371-372. [Volledige tekst]

Castelein S, Bruggeman R, Davidson L, Gaag M. (2015). Creating a Supportive Environment: Peer Support Groups for Psychotic Disorders. Schizophrenia Bulletin, 41: 1211-1213. [Volledige tekst]

Castelein S, Liemburg EJ, Lange de JS, Es van FD, Visser E, Aleman A, Bruggeman R, Knegtering H. (2015). Suicide in Recent Onset Psychosis Revisited: Significant Reduction of Suicide Rate over the Last Two Decades – A Replication Study of a Dutch Incidence Cohort. PloS One, 10: e0129263. [Volledige tekst]

Castelein S, Liemburg EJ, Lange de JS, Es van FD, Visser E, Aleman A, Bruggeman R, Knegtering H. (2015). Suicide Revisited: Significant Reduction of Suicide Rate over the Last Two Decades – a Replication Study of a Dutch Incidence Cohort with Recent Onset Psychosis. European Psychiatry, 30: 967. [Abstract] [Volledige tekst]

Castelein S, Liemburg EJ, Lange de JS, Es van FD, Visser E, Aleman A, Bruggeman R, Knegtering R. (2015). Suicide in Recent Onset Psychosis Revisited: Significant Reduction of Suicide Rate over the Last Two Decades – A Replication Study of a Dutch Incidence Cohort. GGzet Wetenschappelijk, 19: 30-45. [Volledige tekst]

Castelein S, Liemburg EJ, Lange de JS, Es van FD, Visser E, Aleman A, Bruggemans R, Knegtering H. (2015). Drop in suicide rate after first psychosis: a comparison with the situation two decades ago. Nederlands Tijdschrift voor Geneeskunde, 159: A9565. [Volledige tekst]

Castelein S, Tasma M, Swart M, Wolters G, Bruggeman R, Knegtering H. (2015). Do Schizophrenia Patients Receive the Care They Need? From Routine Outcome Monitoring to Evidence Based Treatment. European Psychiatry, 30: 926. [Abstract] [Volledige tekst]

Dam van DS, Nierop van M, Viechtbauer W, Velthorst E, Winkel van R, Genetic Risk and Outcome of Psychosis (GROUP) investigators, Bruggeman R, Cahn W, Haan de L, Kahn RS, Meijer CJ, Myin-Germeys I, Os van J, Wiersma D. (2015). Childhood abuse and neglect in relation to the presence and persistence of psychotic and depressive symptomatology. Psychological Medicine, 45: 1363-1377. [Volledige tekst]

Hanssen E, Velde van der J, Gromann PM, Shergill SS, Haan de L, Bruggeman R, Krabbendam L, Aleman A, Atteveldt van N. (2015). Neural correlates of reward processing in healthy siblings of patients with schizophrenia. Frontiers in Human Neuroscience, 9: 504. [Volledige tekst]

Islam MA, Alizadeh BZ, Heuvel van den ER, GROUP Investigators (Bruggeman R, Cahn W, Haan de L, Kahn RS, Meijer C, Myin-Germeys I, Os van J, Wiersma D. (2015). A comparison of indices for identifying the number of clusters in hierarchical clustering: A study on cognition in schizophrenia patients. Communications in Statistics, 1: 98-113. [Volledige tekst]

Kamphuis J, Taxis K, Schuiling-Veninga CC, Bruggeman R, Lancel M. (2015). Off-Label Prescriptions of Low-Dose Quetiapine and Mirtazapine for Insomnia in The Netherlands. Journal of Clinical Psychopharmacology, 35: 468-470. [Volledige tekst]

Liemburg EJ, Castelein S, Es van FD, Scholte-Stalenhoef AN, Willige van de G, Smid H, Visser E, Knegtering R, Bruggeman R. (2015). The Psychosis Recent Onset GRoningen Survey (PROGR-S): defining dimensions and improving outcomes in early psychosis. GGzet Wetenschappelijk, 19: 56-73. [Volledige tekst]

Maat A, Montfort van SJ, Nijs de J, Derks EM, Kahn RS, Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I, GROUP Investigators. (2015). Emotion processing in schizophrenia is state and trait dependent. Schizophrenia Research, 161: 392-398. [Volledige tekst]

Meer van der L, Stiekema APM, Quee PJ, Dethmers M, Heuvel van den E, Redmeijer JE, Rietberg K, Stant D, Swart M, Weeghel van J, Aleman A, Velligan DI, Schoevers R, Bruggeman R. (2015). Cognitive Adaptation Training as a Nursing Intervention in Long-Term Residential Patients with Severe Mental Illness: a Multicenter Cluster Randomized Controlled Trial. Schizophrenia Bulletin, 41: S194-S195. [Abstract]

Schirmbeck F, Boyette LL, Valk van der R, Meijer C, Dingemans P, Van R, Haan de L, GROUP, Kahn RS, Haan de L, Os van J, Wiersma D, Bruggeman R, Cahn W, Meijer C, Myin-Germeys I. (2015). Relevance of Five-Factor Model personality traits for obsessive-compulsive symptoms in patients with psychotic disorders and their un-affected siblings. Psychiatry Research, 225: 464-470. [Volledige tekst]

Stiekema AP, Quee PJ, Dethmers M, Heuvel van den ER, Redmeijer JE, Rietberg K, Stant AD, Swart M, Weeghel van J, Aleman A, Velligan DI, Schoevers RA, Bruggeman R, Meer van der L. (2015). Effectiveness and cost-effectiveness of cognitive adaptation training as a nursing intervention in long-term residential patients with severe mental illness: study protocol for a randomized controlled trial. Trials, 16: 49-015-0566-8. [Volledige tekst]

Velde van der J, Gromann PM, Swart M, Haan de L, Wiersma D, Bruggeman R, Krabbendam L, Aleman A. (2015). Grey matter, an endophenotype for schizophrenia? A voxel-based morphometry study in siblings of patients with schizophrenia. Journal of Psychiatry & Neuroscience; 40: 207-213. [Volledige tekst]

Velde van der J, Gromann PM, Swart M, Wiersma D, Haan de L, Bruggeman R, Krabbendam L, Aleman A. (2015). Alexithymia influences brain activation during emotion perception but not regulation. Social Cognitive and Affective Neuroscience, 10: 285-293. [Volledige tekst]

Velde van der J, Opmeer EM, Liemburg EJ, Bruggeman R, Nieboer R, Wunderink L, Aleman A. (2015). Lower prefrontal activation during emotion regulation in subjects at ultrahigh risk for psychosis: an fMRI-study. NPJ Schizophrenia, 15026: [Volledige tekst]

Velde van der J, Swart M, Rijn van S, Meer van der L, Wunderink L, Wiersma D, Krabbendam L, Bruggeman R, Aleman A. (2015). Cognitive alexithymia is associated with the degree of risk for psychosis. PloS One, 10: e0124803. [Volledige tekst]

Vercammen A, Knegtering H, Bruggeman R, Westenbroek HM, Jenner JA, Slooff CJ, Wunderink L, Aleman A. (2015). Corrigendum to “Effects of bilateral repetitive transcranial magnetic stimulation on treatment resistant auditory-verbal hallucinations in schizophrenia: A randomized controlled trial”[Schizophr. Res. 114 (1-3) (October 2009) 172-179]. Schizophrenia Research, 168: 599-600. [Volledige tekst]

Wiersma D, Visser E, Bahler M, Bruggeman R, Delespaul PA, Gaag van der M, Haan de L, Keet IP, Nijssen Y, Os van J, Pijnenborg GH, Slooff C, Swildens W, Vos de AE, Weeghel van J, Wunderink L, Mulder CL. (2015). Functional remission of people with serious mental illness (SMI): psychometric properties of a new ROM-instrument. Tijdschrift voor Psychiatrie, 57: 395-404. [Volledige tekst]

Abou Farha K, Bruggeman R, Balje-Volkers C. (2014). Metabotropic glutamate receptor 5 negative modulation in phase I clinical trial: potential impact of circadian rhythm on the neuropsychiatric adverse reactions-do hallucinations matter? ISRN Psychiatry, 2014: 652750. Mar 4

Aleman A, Velde van der J, Gromann P, Swart M, Haan de L, Wiersma D, Krabbendam L, Bruggeman R. (2014). Alexithymia and Emotion Regulation Strategies in First-degree Relatives of Schizophrenia Patients. Schizophrenia Research. 153 Suppl.1:

Apeldoorn SY, Sterk B, Heuvel van den ER, Schoevers RA, Islam MA, Genetic Risk and Outcome of Psychosis (GROUP) Investigators, Bruggeman R, Cahn W, Haan de L, Kahn RS, Meijer CJ, Myin-Germeys I, Os van J, Wiersma D. (2014). Factors contributing to the duration of untreated psychosis. Schizophrenia research, 158: 76-81. [Volledige tekst]

Bartels-Velthuis AA, Hoenders R, Vollbehr N, Bruggeman R, Knegtering R, Jong de J. (2014). Natural Medicines in Schizophrenia: A Systematic Review. Schizophrenia Research. 153 Suppl.1:

Borglum AD, Demontis D, Grove J, Pallesen J, Hollegaard MV, Pedersen CB, Hedemand A, Mattheisen M, GROUP Investigators (Kahn RS, Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I), Uitterlinden A, Nyegaard M, Orntoft T, Wiuf C, Didriksen M, Nordentoft M, Nothen MM, Rietschel M, Ophoff RA, Cichon S, Yolken RH, Hougaard DM, Mortensen PB, Mors O. (2014). Genome-wide study of association and interaction with maternal cytomegalovirus infection suggests new schizophrenia loci. Molecular Psychiatry, 19: 325-333. [volledige tekst]

Boyette LL, Korver-Nieberg N, Meijer C, Haan de L, Genetic Risk and Outcome of Psychosis (GROUP) Investigators (Kahn,R.S., Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I). (2014). Quality of life in patients with psychotic disorders: impact of symptoms, personality, and attachment. Journal of Nervous and Mental Disease, 202: 64-69. [volledige tekst]

Boyette LL, van Dam D, Meijer C, Velthorst E, Cahn W, de Haan L, GROUP, Kahn R, de Haan L, van Os J, Wiersma D, Bruggeman R, Cahn W, Meijer C, Myin-Germeys I. (2014). Personality compensates for impaired quality of life and social functioning in patients with psychotic disorders who experienced traumatic events. Schizophrenia bulletin, 40: 1356-1365. Nov

Bruins J, Jörg F, Bruggeman R, Slooff C, Corpeleijn E, Pijnenborg M. (2014). The effects of lifestyle interventions on (long-term) weight management, cardiometabolic risk and depressive symptoms in people with psychotic disorders: a meta-analysis. PloS one, 9: e112276. [volledige tekst]

Castelein S, Swart M, Wolters G, Bruggeman R, Knegtering H. (2014). Does Routine Outcome Monitoring in Schizophrenia Improve the Implementation of Evidence Based Care? Schizophrenia Research. 153 Suppl.1:

European Network of National Networks studying Gene-Environment Interactions in Schizophrenia (EU-GEI), van Os J, Rutten BP, Myin-Germeys I, Delespaul P, Viechtbauer W, van Zelst C, Bruggeman R, Reininghaus U, Morgan C, Murray RM, Di Forti M, McGuire P, Valmaggia LR, Kempton MJ, Gayer-Anderson C, Hubbard K, Beards S, Stilo SA, Onyejiaka A, Bourque F, Modinos G, Tognin S, Calem M, O’Donovan MC, Owen MJ, Holmans P, Williams N, Craddock N, Richards A, Humphreys I, Meyer-Lindenberg A, Leweke FM, Tost H, Akdeniz C, Rohleder C, Bumb JM, Schwarz E, Alptekin K, Ucok A, Saka MC, Atbasoglu EC, Guloksuz S, Gumus-Akay G, Cihan B, Karadag H, Soygur H, Cankurtaran ES, Ulusoy S, Akdede B, Binbay T, Ayer A, Noyan H, Karadayi G, Akturan E, Ulas H, Arango C, Parellada M, Bernardo M, Sanjuan J, Bobes J, Arrojo M, Santos JL, Cuadrado P, Rodriguez Solano JJ, Carracedo A, Garcia Bernardo E, Roldan L, Lopez G, Cabrera B, Cruz S, Diaz Mesa EM, Pouso M, Jimenez E, Sanchez T, Rapado M, Gonzalez E, Martinez C, Sanchez E, Olmeda MS, de Haan L, Velthorst E, van der Gaag M, Selten JP, van Dam D, van der Ven E, van der Meer F, Messchaert E, Kraan T, Burger N, Leboyer M, Szoke A, Schurhoff F, Llorca PM, Jamain S, Tortelli A, Frijda F, Vilain J, Galliot AM, Baudin G, Ferchiou A, Richard JR, Bulzacka E, Charpeaud T, Tronche AM, De Hert M, van Winkel R, Decoster J, Derom C, Thiery E, Stefanis NC, Sachs G, Aschauer H, Lasser I, Winklbaur B, Schlogelhofer M, Riecher-Rossler A, Borgwardt S, Walter A, Harrisberger F, Smieskova R, Rapp C, Ittig S, Soguel-dit-Piquard F, Studerus E, Klosterkotter J, Ruhrmann S, Paruch J, Julkowski D, Hilboll D, Sham PC, Cherny SS, Chen EY, Campbell DD, Li M, Romeo-Casabona CM, Emaldi Cirion A, Urruela Mora A, Jones P, Kirkbride J, Cannon M, Rujescu D, Tarricone I, Berardi D, Bonora E, Seri M, Marcacci T, Chiri L, Chierzi F, Storbini V, Braca M, Minenna MG, Donegani I, Fioritti A, La Barbera D, La Cascia CE, Mule A, Sideli L, Sartorio R, Ferraro L, Tripoli G, Seminerio F, Marinaro AM, McGorry P, Nelson B, Amminger GP, Pantelis C, Menezes PR, Del-Ben CM, Gallo Tenan SH, Shuhama R, Ruggeri M, Tosato S, Lasalvia A, Bonetto C, Ira E, Nordentoft M, Krebs MO, Barrantes-Vidal N, Cristobal P, Kwapil TR, Brietzke E, Bressan RA, Gadelha A, Maric NP, Andric S, Mihaljevic M, Mirjanic T. (2014). Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations. Schizophrenia bulletin, 40: 729-736. Jul

Hoenders R, Bartels-Velthuis A, Vollbehr N, Bruggeman R, Knegtering R, Jong de J. (2014). Natural Medicines in Schizophrenia: A Systematic Review. Journal of Alternative and Complementary Medicine, 20: A79-A80.

Lako IM, Liemburg EJ, Heuvel van den ER, Knegtering H, Bruggeman R, Taxis K. (2014). Estimating dopamine D(2) receptor occupancy for doses of 8 antipsychotics: a meta-analysis: a reply. Journal of Clinical Psychopharmacology, 34: 532-533. [volledige tekst]

Lataster T, Verweij K, Viechtbauer W, GROUP (Kahn RS, Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I). (2014). Effect of illness expression and liability on familial associations of clinical and subclinical psychosis phenotypes. Acta Psychiatrica Scandinavica, 129: 44-53. [volledige tekst]

Liemburg E, Castelein S, Visser E, Smid D, Hag van ‘t E, Es van FD, Scholte AN, Willige van de G, Bruggeman R, Knegtering H. (2014). The Psychosis Recent Onset GRoningen Survey (PROGR-S): Defining Dimensions and Improving Outcome in Early Psychosis. Schizophrenia Research. 153 Suppl.1:

Liemburg EJ, Castelein S, Es van F, Scholte-Stalenhoef AN, Willige van de G, Smid H, Visser E, Knegtering H, Bruggeman R. (2014). The Psychosis Recent Onset GRoningen Survey (PROGR-S): defining dimensions and improving outcomes in early psychosis. PloS one, 9: e113521. [volledige tekst]

Looijmans A, Jörg F, Schoevers RA, Bruggeman R, Stolk RP, Corpeleijn E. (2014). Changing the obesogenic environment of severe mentally ill residential patients: ELIPS, a cluster randomised study design. BMC psychiatry, 14: 293. [volledige tekst]

Maat A, Montfort van SJ, Nijs de J, Derks EM, Kahn RS, Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I, GROUP Investigators. (2014). Emotion processing in schizophrenia is state and trait dependent. Schizophrenia research, [volledige tekst]

Meer van der L, Swart M, Velde van der J, Pijnenborg G, Wiersma D, Bruggeman R, Aleman A. (2014). Neural correlates of emotion regulation in patients with schizophrenia and non-affected siblings. PloS one, 9: e99667. [Volledige tekst]

Psychosis Endophenotypes International Consortium, Wellcome Trust Case-Control Consortium 2, Bramon E, Pirinen M, Strange A, Lin K, Freeman C, Bellenguez C, Su Z, Band G, Pearson R, Vukcevic D, Langford C, Deloukas P, Hunt S, Gray E, Dronov S, Potter SC, Tashakkori-Ghanbaria A, Edkins S, Bumpstead SJ, Arranz MJ, Bakker S, Bender S, Bruggeman R, Cahn W, Chandler D, Collier DA, Crespo-Facorro B, Dazzan P, Haan de L, Di Forti M, Dragovic M, Giegling I, Hall J, Iyegbe C, Jablensky A, Kahn RS, Kalaydjieva L, Kravariti E, Lawrie S, Linszen DH, Mata I, McDonald C, McIntosh A, Myin-Germeys I, Ophoff RA, Pariante CM, Paunio T, Picchioni M, Psychiatric Genomics Consortium, Ripke S, Rujescu D, Sauer H, Shaikh M, Sussmann J, Suvisaari J, Tosato S, Toulopoulou T, Os van J, Walshe M, Weisbrod M, Whalley H, Wiersma D, Blackwell JM, Brown MA, Casas JP, Corvin A, Duncanson A, Jankowski JA, Markus HS, Mathew CG, Palmer CN, Plomin R, Rautanen A, Sawcer SJ, Trembath RC, Wood NW, Barroso I, Peltonen L, Lewis CM, Murray RM, Donnelly P, Powell J, Spencer CC. (2014). A genome-wide association analysis of a broad psychosis phenotype identifies three loci for further investigation. Biological Psychiatry, 75: 386-397. [Volledige tekst]

Quee PJ, Alizadeh BZ, Aleman A, Heuvel van den ER, GROUP Investigators (Kahn RS, Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I). (2014). Cognitive subtypes in non-affected siblings of schizophrenia patients: characteristics and profile congruency with affected family members. Psychological Medicine, 44: 395-405. [volledige tekst]

Quee PJ, Meer van der L, Krabbendam L, Haan de L, Cahn W, Wiersma D, Beveren van N, Pijnenborg GH, Mulder CL, Bruggeman R, Aleman A. (2014). Insight change in psychosis: relationship with neurocognition, social cognition, clinical symptoms and phase of illness. Acta Psychiatrica Scandinavica, 129: 126-133. [Volledige tekst]

Quee PJ, Stiekema AP, Wigman JT, Schneider H, Meer van der L, Maples NJ, Heuvel van den ER, Velligan DI, Bruggeman R. (2014). Improving functional outcomes for schizophrenia patients in the Netherlands using Cognitive Adaptation Training as a nursing intervention – A pilot study. Schizophrenia research, 158: 120-125. [Volledige tekst]

Redmeijer J, Quee P, Stiekema A, Wigman J, Schneider H, Meer van der L, Maples N, Wiersma D, Heuvel van den E, Velligan D, Bruggeman R. (2014). Improving Functional Outcomes for Schizophrenia Patients in the Netherlands using Cognitive Adaptation Training as a Nursing Intervention – A Pilot Study. Schizophrenia Research. 153 Suppl.1:

Stiekema APM, Looijmans A, Meer van der L, Dethmers M, Schoevers R, Bruggeman R, Corpeleijn E, Jörg F. (2014). The Effect of Lifestyle Interventions on Psychosocial Functioning and Well-Being in Patients wiht Severe Mental Illnes. Schizophrenia Research. 153 Suppl.1:

Tol van MJ, Liemburg E, Meer van der L, Pijnenborg M, Opmeer E, Bruggeman R, Knegtering H, Aleman A. (2014). Apathy in Schizophrenia: Are Structural Abnormalities in Primary Emotion Processing Areas Involved? Schizophrenia Research. 153 Suppl.1:

Tol van MJ, Meer van der L, Bruggeman R, Modinos G, Knegtering H, Aleman A. (2013). Voxel-based gray and white matter morphometry correlates of hallucinations in schizophrenia: The superior temporal gyrus does not stand alone. NeuroImage.Clinical, 4: 249-257. [volledige tekst]

Velde van der J, Gromann P, Swart M, Haan de L, Bruggeman R, Wiersma D, Krabbendam L, Aleman A. (2014). Is Gray Matter Volume a Structural Endophenotype for Schizophrenia? Schizophrenia Research. 153 Suppl.1:

Velde van der J, Tol van MJ, Goerlich-Dobre KS, Gromann PM, Swart M, Haan de L, Wiersma D, Bruggeman R, Krabbendam L, Aleman A. (2014). Dissociable morphometric profiles of the affective and cognitive dimensions of alexithymia. Cortex, 54: 190-199. [volledige tekst]

Won S, Kwon MS, Mattheisen M, Park S, Park C, Kihara D, Cichon S, Ophoff R, Nothen MM, Rietschel M, Baur M, Uitterlinden AG, Hofmann A, GROUP Investigators (Kahn RS, Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I), Lange C. (2014). Efficient strategy for detecting gene x gene joint action and its application in schizophrenia. Genetic Epidemiology, 38: 60-71. [Volledige tekst]

Bais L, Vercammen A, Knegtering H, Bruggeman R, Aleman A. (2013). Long term effect of repetitive transcranial magnetic stimulation treatment for auditory verbal hallucinations. Schizophrenia Bulletin. 39S1: S321

Berg van den SM, Paap MC, Derks EM, GROUP Investigators (Kahn RS, Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I). (2013). Using multidimensional modeling to combine self-report symptoms with clinical judgment of schizotypy. Psychiatry Res. 206: 75-80 [PubMed]

Boyette LL, Korver-Nieberg N, Verweij K, Meijer C, Dingemans P, Cahn W, Haan de L, GROUP (Kahn RS, Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I). (2013). Associations between the Five-Factor Model personality traits and psychotic experiences in patients with psychotic disorders, their siblings and controls. Psychiatry Res. 210: 491-7 [PubMed]

Cross-Disorder Group of the Psychiatric Genomics Consortium, Lee SH, Ripke S, Neale BM, Faraone SV, Purcell SM, Perlis RH, Mowry BJ, Thapar A, Goddard ME, Witte JS, Absher D, Agartz I, Akil H, Amin F, Andreassen OA, Anjorin A, Anney R, Anttila V, Arking DE, Asherson P, Azevedo MH, Backlund L, Badner JA, Bailey AJ, Banaschewski T, Barchas JD, Barnes MR, Barrett TB, Bass N, Battaglia A, Bauer M, Bayes M, Bellivier F, Bergen SE, Berrettini W, Betancur C, Bettecken T, Biederman J, Binder EB, Black DW, Blackwood DH, Bloss CS, Boehnke M, Boomsma DI, Breen G, Breuer R, Bruggeman R, Cormican P, Buccola NG, Buitelaar JK, Bunney WE, Buxbaum JD, Byerley WF, Byrne EM, Caesar S, Cahn W, Cantor RM, Casas M, Chakravarti A, Chambert K, Choudhury K, Cichon S, Cloninger CR, Collier DA, Cook EH, Coon H, Cormand B, Corvin A, Coryell WH, Craig DW, Craig IW, Crosbie J, Cuccaro ML, Curtis D, Czamara D, Datta S, Dawson G, Day R, Geus de EJ, Degenhardt F, Djurovic S, Donohoe GJ, Doyle AE, Duan J, Dudbridge F, Duketis E, Ebstein RP, Edenberg HJ, Elia J, Ennis S, Etain B, Fanous A, Farmer AE, Ferrier IN, Flickinger M, Fombonne E, Foroud T, Frank J, Franke B, Fraser C, Freedman R, Freimer NB, Freitag CM, Friedl M, Frisen L, Gallagher L, Gejman PV, Georgieva L, Gershon ES, Geschwind DH, Giegling I, Gill M, Gordon SD, Gordon-Smith K, Green EK, Greenwood TA, Grice DE, Gross M, Grozeva D, Guan W, Gurling H, Haan de L, Haines JL, Hakonarson H, Hallmayer J, Hamilton SP, Hamshere ML, Hansen TF, Hartmann AM, Hautzinger M, Heath AC, Henders AK, Herms S, Hickie IB, Hipolito M, Hoefels S, Holmans PA, Holsboer F, Hoogendijk WJ, Hottenga JJ, Hultman CM, Hus V, Ingason A, Ising M, Jamain S, Jones EG, Jones I, Jones L, Tzeng JY, Kahler AK, Kahn RS, Kandaswamy R, Keller MC, Kennedy JL, Kenny E, Kent L, Kim Y, Kirov GK, Klauck SM, Klei L, Knowles JA, Kohli MA, Koller DL, Konte B, Korszun A, Krabbendam L, Krasucki R, Kuntsi J, Kwan P, Landen M, Langstrom N, Lathrop M, Lawrence J, Lawson WB, Leboyer M, Ledbetter DH, Lee PH, Lencz T, Lesch KP, Levinson DF, Lewis CM, Li J, Lichtenstein P, Lieberman JA, Lin DY, Linszen DH, Liu C, Lohoff FW, Loo SK, Lord C, Lowe JK, Lucae S, MacIntyre DJ, Madden PA, Maestrini E, Magnusson PK, Mahon PB, Maier W, Malhotra AK, Mane SM, Martin CL, Martin NG, Mattheisen M, Matthews K, Mattingsdal M, McCarroll SA, McGhee KA, McGough JJ, McGrath PJ, McGuffin P, McInnis MG, McIntosh A, McKinney R, McLean AW, McMahon FJ, McMahon WM, McQuillin A, Medeiros H, Medland SE, Meier S, Melle I, Meng F, Meyer J, Middeldorp CM, Middleton L, Milanova V, Miranda A, Monaco AP, Montgomery GW, Moran JL, Moreno-De-Luca D, Morken G, Morris DW, Morrow EM, Moskvina V, Muglia P, Muhleisen TW, Muir WJ, Muller-Myhsok B, Murtha M, Myers RM, Myin-Germeys I, Neale MC, Nelson SF, Nievergelt CM, Nikolov I, Nimgaonkar V, Nolen WA, Nothen MM, Nurnberger JI, Nwulia EA, Nyholt DR, O’Dushlaine C, Oades RD, Olincy A, Oliveira G, Olsen L, Ophoff RA, Osby U, Owen MJ, Palotie A, Parr JR, Paterson AD, Pato CN, Pato MT, Penninx BW, Pergadia ML, Pericak-Vance MA, Pickard BS, Pimm J, Piven J, Posthuma D, Potash JB, Poustka F, Propping P, Puri V, Quested DJ, Quinn EM, Ramos-Quiroga JA, Rasmussen HB, Raychaudhuri S, Rehnstrom K, Reif A, Ribases M, Rice JP, Rietschel M, Roeder K, Roeyers H, Rossin L, Rothenberger A, Rouleau G, Ruderfer D, Rujescu D, Sanders AR, Sanders SJ, Santangelo SL, Sergeant JA, Schachar R, Schalling M, Schatzberg AF, Scheftner WA, Schellenberg GD, Scherer SW, Schork NJ, Schulze TG, Schumacher J, Schwarz M, Scolnick E, Scott LJ, Shi J, Shilling PD, Shyn SI, Silverman JM, Slager SL, Smalley SL, Smit JH, Smith EN, Sonuga-Barke EJ, St.Clair D, State M, Steffens M, Steinhausen HC, Strauss JS, Strohmaier J, Stroup TS, Sutcliffe JS, Szatmari P, Szelinger S, Thirumalai S, Thompson RC, Todorov AA, Tozzi F, Treutlein J, Uhr M, Oord van den EJ, Grootheest van G, Os van J, Vicente AM, Vieland VJ, Vincent JB, Visscher PM, Walsh CA, Wassink TH, Watson SJ, Weissman MM, Werge T, Wienker TF, Wijsman EM, Willemsen G, Williams N, Willsey AJ, Witt SH, Xu W, Young AH, Yu TW, Zammit S, Zandi PP, Zhang P, Zitman FG, Zollner S, International Inflammatory Bowel Disease Genetics Consortium (IIBDGC), Devlin B, Kelsoe JR, Sklar P, Daly MJ, O’Donovan MC, Craddock N, Sullivan PF, Smoller JW, Kendler KS, Wray NR. (2013). Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat.Genet. 45: 984-94 [PubMed]

Curcic-Blake B, Liemburg E, Vercammen A, Swart M, Knegtering H, Bruggeman R, Aleman A. (2013). When Broca Goes Uninformed: Reduced Information Flow to Broca’s Area in Schizophrenia Patients With Auditory Hallucinations. Schizophr.Bull. 39: 1087-95 [PubMed]

Dekker N, Swets M, GROUP Investigators (Kahn RS, Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I). (2013). Substance use in a large sample of patients with schizophrenia or related disorders and co-morbid obsessive-compulsive symptoms. Aust.N.Z.J.Psychiatry. 47: 868-74 [PubMed]

Derks EM, Ophoff RA, Genetic Risk Outcome of Psychosis (GROUP: Kahn,R.S., Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I). (2013). Replication and refinement of the role of rs548181 in schizophrenia: results from a family based study. Am.J.Med.Genet.B.Neuropsychiatr.Genet. 162: 75-7 [PubMed]

Fett AK, Maat A, GROUP Investigators (Kahn RS, Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I). (2013). Social cognitive impairments and psychotic symptoms: what is the nature of their association?. Schizophr.Bull. 39: 77-85 [PubMed]

Heering HD, Haren van NE, Derks EM, GROUP Investigators (Kahn RS, Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I). (2013). A two-factor structure of first rank symptoms in patients with a psychotic disorder. Schizophr.Res. 147: 269-74 [PubMed]

Klaassen RM, Heins M, Luteijn LB, Gaag van der M, Beveren van NJ, GROUP Investigators (Kahn RS, Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I). (2013). Depressive symptoms are associated with (sub)clinical psychotic symptoms in patients with non-affective psychotic disorder, siblings and healthy controls. Psychol.Med. 43: 747-56 [PubMed]

Klerk de OL, Nolte IM, Bet PM, Bosker FJ, Snieder H, Boer den JA, Bruggeman R, Hoogendijk WJ, Penninx BW. (2013). ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder. Pharmacogenomics J. Pharmacogenomics J.: 349-53 [PubMed]

Lako IM, Bruggeman R, Liemburg EJ, Heuvel van den ER, Knegtering H, Slooff CJ, Wiersma D, Taxis K. (2013). A brief version of the Subjects’ Response to Antipsychotics questionnaire to evaluate treatment effects. Schizophr.Res. 147: 175-80 [PubMed]

Lako IM, Heuvel van den ER, Knegtering H, Bruggeman R, Taxis K. (2013). Estimating dopamine D(2) receptor occupancy for doses of 8 antipsychotics: a meta-analysis. J.Clin.Psychopharmacol. 33: 675-81 [PubMed]

Meijer JH, Swets M, Keeman S, Nieman DH, Meijer CJ, GROUP Investigators (Kahn RS, Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I). (2013). Is a schizo-obsessive subtype associated with cognitive impairment? Results from a large cross-sectional study in patients with psychosis and their unaffected relatives. J.Nerv.Ment.Dis. 201: 30-5 [PubMed]

Nierop van M, Janssens M, Genetic Risk OUtcome of Psychosis Investigators, Bruggeman R, Cahn W, Haan de L, Kahn RS, Meijer CJ, Myin-Germeys I, Os van J, Wiersma D. (2013). Evidence that transition from health to psychotic disorder can be traced to semi-ubiquitous environmental effects operating against background genetic risk. PLoS One. 8: e76690 [PubMed]

Simons CJ, Winkel van R, GROUP (Kahn RS, Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I). (2013). Intermediate phenotype analysis of patients, unaffected siblings, and healthy controls identifies VMAT2 as a candidate gene for psychotic disorder and neurocognition. Schizophr.Bull. 39: 848-56 [PubMed]

Smid HG, Bruggeman R, Martens S. (2013). Fragmented perception: slower space-based but faster object-based attention in recent-onset psychosis with and without Schizophrenia. PLoS One. 8: e59983 [PubMed]

Smid HG, Martens S, Witte de MR, Bruggeman R. (2013). Inflexible minds: impaired attention switching in recent-onset schizophrenia. PLoS One. 8: e78062 [PubMed]

Swart M, Liemburg EJ, Kortekaas R, Wiersma D, Bruggeman R, Aleman A. (2013). Normal brain activation in schizophrenia patients during associative emotional learning. Psychiatry Res. 214: 269-76 [PubMed]

Tol van MJ, Meer van der L, Bruggeman R, Modinos G, Knegtering H, Aleman A. (2013). Voxel-based grey and white matter morphometry correlates of auditory verbal hallucinations in schizophrenia: relevance of posterior parietal areas. Schizophrenia Bulletin. 39S1: S198

Velde van der J, Servaas MN, Goerlich KS, Bruggeman R, Horton P, Costafreda SG, Aleman A. (2013). Neural correlates of alexithymia: a meta-analysis of emotion processing studies. Neurosci.Biobehav.Rev. 37: 1774-85 [PubMed]

Vinkers CH, Gastel van WA, Schubart CD, Eijk van KR, Luykx JJ, Winkel van R, Joels M, Ophoff RA, Boks MP, Genetic Risk and OUtcome of Psychosis (GROUP) Investigators, Bruggeman R, Cahn W, Haan de L, Kahn RS, Meijer CJ, Myin-Germeys I, Os van J, Wiersma D. (2013). The effect of childhood maltreatment and cannabis use on adult psychotic symptoms is modified by the COMT Val(1)(5)(8)Met polymorphism. Schizophr.Res. 150: 303-11 [PubMed]

Vliet van IM, Well van EP, Bruggeman R, Campo JA, Hijman R, Megen van HJ, Balkom van AJ, Rijen van PC. (2013). An evaluation of irreversible psychosurgical treatment of patients with obsessive-compulsive disorder in the Netherlands, 2001-2008. J.Nerv.Ment.Dis. 201: 226-8 [PubMed]

Abou Farha K, Vliet van A, Knegtering H, Bruggeman R. (2012). The Value of Desmethylclozapine and Serum CRP in Clozapine Toxicity: A Case Report. Case Rep.Psychiatry.: 592784 [PubMed]

Al Hadithy A, Leeffers E, Bruggeman R. (2012). Clozapine levels might be affected by excessive cola consumption. J.Clin.Psychopharmacol. 32: 717-9 [PubMed]

Alphen van C, Ammeraal M, Blanke C, Boonstra N, Boumans H, Bruggeman R, Castelein S, Dekker FL, Duin van D, Ewijk van WM, Gaag van der M, Gool van R, Haas de O, Henquet C, Hermens MLM, Ketelaars T, Knegtering H, Krans MJ, Lansen M, Lochy R, Loonen AJM, Meesters PD, Meijel van BKG, Miltenburg G, Oud MJT, Pater de CF, Peterse A, Plas van der J, Rammers D, Rentenaar IMF, Santen van GW, Scheewe TW, Selten JP, Slooff CJAJ, Stoop C, Vlaminck P, Vollaard H, Weeghel van J, Wel van T, Zon van N. (2012). Multidisciplinaire Richtlijn Schizofrenie. Utrecht: De Tijdstroom

Bruggeman R, Knegtering H. (2012). Chapter on medication strategies (Juiste titel volgt). In: Anonymous Update Dutch Guidelines Schizophrenia. Utrecht: Kenniscentrum Phrenos

Dekker N, Koeter M, Brink van den W, GROUP Investigators (Kahn RS, Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I). (2012). Craving for cannabis in patients with psychotic disorder, their non-affected siblings and healthy controls: psychometric analysis of the obsessive compulsive drug use scale. Int.J.Methods Psychiatr.Res. 21: 286-300 [PubMed]

Dekker N, Meijer J, Koeter M, Brink van den W, Beveren van N, GROUP Investigators (Kahn RS, Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I. (2012). Age at onset of non-affective psychosis in relation to cannabis use, other drug use and gender. Psychol.Med. 42: 1903-11 [PubMed]

Derks EM, Allardyce J, Boks MP, Vermunt JK, Hijman R, Ophoff RA, GROUP Investigators (Kahn RS, Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I). (2012). Kraepelin was right: a latent class analysis of symptom dimensions in patients and controls. Schizophr.Bull. 38: 495-505 [PubMed]

Gladwin TE, Derks EM, Genetic Risk and Outcome of Psychosis (GROUP: Kahn,R.S., Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I), Rietschel M, Mattheisen M, Breuer R, Schulze TG, Nothen MM, Levinson D, Shi J, Gejman PV, Cichon S, Ophoff RA. (2012). Segment-wise genome-wide association analysis identifies a candidate region associated with schizophrenia in three independent samples. PloS One. 7: e38828 [PubMed]

Ketelaars T, Bruggeman R, Bogers J, Cohen D, Haan de L, Harten van PN, Hert de M, Knegtering H, Loonen A, Moleman P, Oud M, Sommer I, Soest van M, Schulte PFJ, Tenback D, Ouwehand J, Wunderink A, Wilffert B. (2012). Biologische behandeling. In: Alphen van C, Ammeraal B,C., Boonstra N, et al (eds). Multidisciplinaire Richtlijn Schizofrenie. Utrecht: De Tijdstroom

Koning JP, Vehof J, Burger H, Wilffert B, Al Hadithy A, Alizadeh B, Harten van PN, Snieder H, Genetic Risk and Outcome in Psychosis (GROUP) investigators (Kahn,R.S., Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I). (2012). Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients. Psychopharmacology. 219: 727-36 [PubMed]

Korver N, Quee PJ, Boos HB, Simons CJ, Haan de L, GROUP Investigators (Kahn RS, Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I). (2012). Genetic Risk and Outcome of Psychosis (GROUP), a multi site longitudinal cohort study focused on gene-environment interaction: objectives, sample characteristics, recruitment and assessment methods. Int.J.Methods Psychiatr.Res. 21: 205-21 [PubMed]

Lako IM, Bruggeman R, Knegtering H, Wiersma D, Schoevers RA, Slooff CJ, Taxis K. (2012). A systematic review of instruments to measure depressive symptoms in patients with schizophrenia. J.Affect.Disord. 140: 38-47 [PubMed]

Lako IM, Taxis K, Bruggeman R, Knegtering H, Burger H, Wiersma D, Slooff CJ. (2012). The course of depressive symptoms and prescribing patterns of antidepressants in schizophrenia in a one-year follow-up study. Eur.Psychiatry. 27: 240-4 [PubMed]

Lataster T, Shazad A, Henquet C, Quee P, GROUP Investigators (Kahn RS, Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I). (2012). No evidence for familial covariation of neurocognition and negative symptoms in psychotic disorders. Schizophr.Res. 139: 271-2 [PubMed]

Liemburg EJ, Meer van der L, Swart M, Curcic-Blake B, Bruggeman R, Knegtering H, Aleman A. (2012). Reduced connectivity in the self-processing network of schizophrenia patients with poor insight. PloS One. 7: e42707 [PubMed]

Liemburg EJ, Swart M, Bruggeman R, Kortekaas R, Knegtering H, Curcic-Blake B, Aleman A. (2012). Altered resting state connectivity of the default mode network in alexithymia. Soc.Cogn.Affect.Neurosci. 7: 660-6 [PubMed]

Maat A, Fett AK, Derks E, GROUP Investigators (Kahn RS, Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I). (2012). Social cognition and quality of life in schizophrenia. Schizophr.Res. 137: 212-8 [PubMed]

Machielsen M, Scheltema Beduin A, Dekker N, Kahn RS, Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I. (2012). Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine. J.Psychopharmacol. 26: 189-95 [PubMed]

Meijer J, Simons CJ, Quee PJ, Verweij K, GROUP Investigators (Kahn RS, Cahn W, Linszen DH, Haan de L, Os van J, Krabbendam L, Myin-Germeys I, Wiersma D, Bruggeman R, Os van J). (2012). Cognitive alterations in patients with non-affective psychotic disorder and their unaffected siblings and parents. Acta Psychiatr.Scand. 125: 66-76 [PubMed]

Meijer JH, Dekker N, Koeter MW, Quee PJ, Beveren van NJ, Meijer CJ, Genetic Risk and Outcome of Psychosis (GROUP) Investigators (Kahn,R.S., Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I). (2012). Cannabis and cognitive performance in psychosis: a cross-sectional study in patients with non-affective psychotic illness and their unaffected siblings. Psychol.Med. 42: 705-16 [PubMed]

Muhleisen TW, Mattheisen M, Strohmaier J, Degenhardt F, Priebe L, Schultz CC, Breuer R, Meier S, Hoffmann P, GROUP Investigators (Kahn RS, Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I), Rivandeneira F, Hofman A, Uitterlinden AG, Moebus S, Gieger C, Emeny R, Ladwig KH, Wichmann HE, Schwarz M, Kammerer-Ciernioch J, Schlosser RG, Nenadic I, Sauer H, Mossner R, Maier W, Rujescu D, Lange C, Ophoff RA, Schulze TG, Rietschel M, Nothen MM, Cichon S. (2012). Association between schizophrenia and common variation in neurocan (NCAN), a genetic risk factor for bipolar disorder. Schizophr.Res. 138: 69-73 [PubMed]

Quee PJ, Schneider H, Slogteren van S, Wiersma D, Bruggeman R, Velligan DI. (2012). Cognitive adaptation training provided to chronically hospitalized patients with schizophrenia in the Netherlands: two case reports. Case Rep.Psychiatry. 2012: 596162 [PubMed]

Quee PJ, Wiersma D, Sytema S, Bruggeman R. (2012). Cognitive adaptation training combined with assertive community treatment: a randomised longitudinal trial–a comment. Schizophr.Res. 140: 264-5 [PubMed]

Rietschel M, Mattheisen M, Degenhardt F, Genetic Risk and Outcome in Psychosis (GROUP) Investigators (Kahn,R.S., Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I), Muhleisen TW, Kirsch P, Esslinger C, Herms S, Demontis D, Steffens M, Strohmaier J, Haenisch B, Breuer R, Czerski PM, Giegling I, Strengman E, Schmael C, Mors O, Mortensen PB, Hougaard DM, Orntoft T, Kapelski P, Priebe L, Basmanav FF, Forstner AJ, Hoffman P, Meier S, Nikitopoulos J, Moebus S, Alexander M, Mossner R, Wichmann H, Schreiber S, Rivandeneira F, Hofman A, Uitterlinden AG, Wienker TF, Schumacher J, Hauser J, Maier W, Cantor RM, Erk S, Schulze TG, SGENE-plus Consortium, Craddock N, Owen MJ, O’Donovan MC, Borglum AD, Rujescu D, Walter H, Meyer-Lindenberg A, Nothen MM, Ophoff RA, Cichon S. (2012). Association between genetic variation in a region on chromosome 11 and schizophrenia in large samples from Europe. Mol.Psychiatry. 17: 906-17 [PubMed]

Rietschel M, Mattheisen M, Degenhardt F, GROUP Investigators (Kahn RS, Linszen DH, Os JV, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I, Muhleisen TW, Kirsch P, Esslinger C, Herms S, Demontis D, Steffens M, Strohmaier J, Haenisch B, Breuer R, Czerski PM, Giegling I, Strengman E, Schmael C, Mors O, Mortensen PB, Hougaard DM, Orntoft T, Kapelski P, Priebe L, Basmanav FB, Forstner AJ, Hoffmann P, Meier S, Nikitopoulos J, Moebus S, Alexander M, Mossner R, Wichmann HE, Schreiber S, Rivandeneira F, Hofman A, Uitterlinden AG, Wienker TF, Schumacher J, Hauser J, Maier W, Cantor RM, Erk S, Schulze TG, SGENE-plus Consortium, (Only those persons responsible for the samples of Replication 2 are listed), Stefansson H, Steinberg S, Gustafsson O, Sigurdsson E, Petursson H, Kong A, Stefansson K, Pietilainen OP, Tuulio-Henriksson A, Paunio T, Lonnqvist J, Suvisaari J, Peltonen L, Ruggeri M, Tosato S, Walshe M, Murray R, Collier DA, Clair DS, Hansen T, Ingason A, Jakobsen KD, Duong L, Werge T, Melle I, Andreassen OA, Djurovic S, Bitter I, Rethelyi JM, Abramova L, Kaleda V, Golimbet V, Jonsson EG, Terenius L, Agartz I, Winkel RV, Kenis G, Hert MD, Veldink J, Wiuf C, Didriksen M, Craddock N, Owen MJ, O’Donovan MC, Borglum AD, Rujescu D, Walter H, Meyer-Lindenberg A, Nothen MM, Ophoff RA, Cichon S. (2012). Association between genetic variation in a region on chromosome 11 and schizophrenia in large samples from Europe. Mol.Psychiatry. 17: 906-17 [PubMed]

Risselada AJ, Vehof J, Bruggeman R, Wilffert B, Cohen D, Al Hadithy AF, Arends J, Mulder H. (2012). Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study. Pharmacogenomics J. 12: 62-7 [PubMed]

Vehof J, Burger H, Wilffert B, Al Hadithy A, Alizadeh BZ, Snieder H, GROUP Investigators (Kahn RS, Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I). (2012). Clinical response to antipsychotic drug treatment: association study of polymorphisms in six candidate genes. Eur.Neuropsychopharmacol. 22: 625-31 [PubMed]

Werf van der M, Kohler S, Verkaaik M, Verhey F, Os van J, GROUP Investigators (Kahn RS, Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I). (2012). Cognitive functioning and age at onset in non-affective psychotic disorder. Acta Psychiatr.Scand. 126: 274-81 [PubMed]

Ackermans L, Duits A, Linden van der C, Tijssen M, Schruers K, Temel Y, Kleijer M, Nederveen P, Bruggeman R, Tromp S, Kranen van-Mastenbroek V, Kingma H, Cath D, Visser-Vandewalle V. (2011). Double-blind clinical trial of thalamic stimulation in patients with Tourette syndrome. Brain. 134: 832-44 [PubMed]

Anani W, Bruggeman R, Zander DS. (2011). Beta-Catenin Expression in Benign and Malignant Pleural Disorders. Int.J.Clin.Exp.Pathol. 4: 742-7

Boyette L, Swets M, Meijer C, Wouters L, G.R.O.U.P. Authors (Kahn RS, Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I). (2011). Factor structure of the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) in a large sample of patients with schizophrenia or related disorders and comorbid obsessive-compulsive symptoms. Psychiatry Res. 186: 409-13 [PubMed]

Bruggeman R, Knegtering H. (2011). Farmacotherapie van psychotische stoornissen 2, praktijk. In: Cahn W, Krabbendam L, Myin-Germeys I, Bruggeman R, Haan de L (eds). Handboek Schizofrenie. Utrecht: De Tijdstroom

Bruggeman R, Knegtering H. (2011). Farmacotherapie van psychotische stoornissen 1, achtergrond. In: Cahn W, Krabbendam L, Myin-Germeys I, Bruggeman R, Haan de L (eds). Handboek Schizofrenie. Utrecht: De Tijdstroom

Bruggeman R, Vehof J, Al Hadithy AF, Burger H, Risselada AJ, Wilffert B, Arends J, Wunderink A, Knegtering H, Cohen D, Mulder H, Schnieder H. (2011). Association of genetic variants of the H1 and M3 receptors with BMI and HbA1c in caucasian patients using antipsychotics. Schizophrenia Bulletin. 37 Suppl.1: 83

Cahn W, Krabbendam L, Myin-Germeys I, Bruggeman R, Haan de L. (2011). Handboek Schizofrenie. Utrecht: De Tijdstroom

Chen X, Lee G, Maher BS, Fanous AH, Chen J, Zhao Z, Guo A, Oord van den E, Sullivan PF, Shi J, Levinson DF, Gejman PV, Sanders A, Duan J, Owen MJ, Craddock NJ, O’Donovan MC, Blackman J, Lewis D, Kirov GK, Qin W, Schwab S, Wildenauer D, Chowdari K, Nimgaonkar V, Straub RE, Weinberger DR, O’Neill FA, Walsh D, Bronstein M, Darvasi A, Lencz T, Malhotra AK, Rujescu D, Giegling I, Werge T, Hansen T, Ingason A, Noethen MM, Rietschel M, Cichon S, Djurovic S, Andreassen OA, Cantor RM, Ophoff R, Corvin A, Morris DW, Gill M, Pato CN, Pato MT, Macedo A, Gurling HM, McQuillin A, Pimm J, Hultman C, Lichtenstein P, Sklar P, Purcell SM, Scolnick E, St.Clair D, Blackwood DH, Kendler KS, GROUP Investigators (Kahn RS, Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I), International Schizophrenia Consortium. (2011). GWA study data mining and independent replication identify cardiomyopathy-associated 5 (CMYA5) as a risk gene for schizophrenia. Mol.Psychiatry. 16: 1117-29 Nov

Collip D, Nicolson NA, Lardinois M, Lataster T, Os van J, Myin-Germeys I, GROUP (Kahn RS, Linszen DH, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L). (2011). Daily cortisol, stress reactivity and psychotic experiences in individuals at above average genetic risk for psychosis. Psychol.Med. 41: 2305-15 [PubMed]

Dlabac-de Lange JJ, Bais L, Aleman A, Bruggeman R, Knegtering H. (2011). Transcraniële magnetische stimulatie bij negatieve en depressieve symptomen in het kader van schizofrenie. In: Pijnenborg GHM, Withaar FK, Slooff CJ, Knegtering H, Gaag van der M (eds). Negatieve symptomen en cognitieve functiestoornissen bij schizofrenie en verwante psychosen. Utrecht: Kenniscentrum Phrenos

Es van FD, Knegtering H, Carbo M, Smid HG, Wiersma D, Bruggeman R. (2011). Gender differences in first episode psychosis- the EPO 500 study. Schizophrenia Bulletin. 37 Suppl.1: 65

Genetic Risk and Outcome in Psychosis (GROUP) Investigators (Kahn,R.S., Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I). (2011). Evidence That Familial Liability for Psychosis Is Expressed as Differential Sensitivity to Cannabis: An Analysis of Patient-Sibling and Sibling-Control Pairs. Arch.Gen.Psychiatry. 68: 132-47 [PubMed]

Habets P, Marcelis M, Gronenschild E, Drukker M, Os van J, Genetic Risk and Outcome of Psychosis (GROUP: Kahn,R.S., Linszen DH, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I). (2011). Reduced cortical thickness as an outcome of differential sensitivity to environmental risks in schizophrenia. Biol.Psychiatry. 69: 487-94 [PubMed]

Ingason A, Rujescu D, Cichon S, Sigurdsson E, Sigmundsson T, Pietilainen OP, Buizer-Voskamp JE, Strengman E, Francks C, Muglia P, Gylfason A, Gustafsson O, Olason PI, Steinberg S, Hansen T, Jakobsen KD, Rasmussen HB, Giegling I, Moller HJ, Hartmann A, Crombie C, Fraser G, Walker N, Lonnqvist J, Suvisaari J, Tuulio-Henriksson A, Bramon E, Kiemeney LA, Franke B, Murray R, Vassos E, Toulopoulou T, Muhleisen TW, Tosato S, Ruggeri M, Djurovic S, Andreassen OA, Zhang Z, Werge T, Ophoff RA, GROUP Investigators (Kahn RS, Cahn W, Linszen D, Haan de L, Os van J, Krabbendam L, Myin-Germeys I, Wiersma D, Bruggeman R), Rietschel M, Nothen MM, Petursson H, Stefansson H, Peltonen L, Collier D, Stefansson K, St Clair DM. (2011). Copy number variations of chromosome 16p13.1 region associated with schizophrenia. Mol.Psychiatry. 16: 17-25 [PubMed]

Knegtering H, Nienhuis F. (2011). De differentiaal diagnostiek van psychotische stoornissen. In: Cahn W, Krabbendam L, Myin-Germeys I, Bruggeman R, Haan de L (eds). Handboek Schizofrenie. Utrecht: De Tijdstroom

Korver-Nieberg N, Quee PJ, Boos HB, Simons CJ, GROUP Investigators (Kahn RS, Linszen DH, Os van J, Krabbendam L, Myin-Germeys I, Wiersma D, Bruggeman R). (2011). The validity of the DSM-IV diagnostic classification system of non-affective psychoses. Aust.N.Z.J.Psychiatry. 45: 1061-8 [PubMed]

Lako IM, Knegtering H, Burger H, Slooff CJ, Taxis K, Bruggeman R. (2011). Patient reports of antipsychotic induced depressive symptoms. Schizophrenia Bulletin. 37 Suppl.1: 27

Looman N, Knegtering H, Slooff CJ, Jörg F, Lako IM, Sytema S, Wiersma D, Taxis K, Bruggeman R. (2011). Somatische screening als onderdeel van de ROM-psychosen; haalbaarheid en resultaten binnen het Phamous-project in Noord-Nederland [Screening for somatic diseases as part of Routine Outcome Monitoring]. Tijdschrift voor Psychiatrie. 53 Suppl.1: 110-1

Nienhuis F, Knegtering H. (2011). Classificatie van psychotische stoornissen. In: Cahn W, Krabbendam L, Myin-Germeys I, Bruggeman R, Haan de L (eds). Handboek Schizofrenie. Utrecht: De Tijdstroom

Quee PJ, Bruggeman R, Schneider H, Velligan DI, Wiersma D. (2011). Cognitieve Adaptatie Training. In: Pijnenborg GHM, Withaar FK, Slooff CJ, Knegtering H, Gaag van der M (eds). Negatieve symptomen en cognitieve functiestoornissen bij schizofrenie en verwante psychosen. Utrecht: Kenniscentrum Phrenos

Quee PJ, Meer van der L, Bruggeman R, Haan de L, Krabbendam L, Cahn W, Mulder NC, Wiersma D, Aleman A. (2011). Insight in psychosis: relationship with neurocognition, social cognition and clinical symptoms depends on phase of illness. Schizophr.Bull. 37: 29-37 [PubMed]

Ripke S, Sanders AR, Kendler KS, Levinson DF, Sklar P, Holmans PA, Lin DY, Duan J, Ophoff RA, Andreassen OA, Scolnick E, Cichon S, St.Clair D, Corvin A, Gurling H, Werge T, Rujescu D, Blackwood DH, Pato CN, Malhotra AK, Purcell S, Dudbridge F, Neale BM, Rossin L, Visscher PM, Posthuma D, Ruderfer DM, Fanous A, Stefansson H, Steinberg S, Mowry BJ, Golimbet V, Hert de M, Jonsson EG, Bitter I, Pietilainen OP, Collier DA, Tosato S, Agartz I, Albus M, Alexander M, Amdur RL, Amin F, Bass N, Bergen SE, Black DW, Borglum AD, Brown MA, Bruggeman R, Buccola NG, Byerley WF, Cahn W, Cantor RM, Carr VJ, Catts SV, Choudhury K, Cloninger CR, Cormican P, Craddock N, Danoy PA, Datta S, Haan de L, Demontis D, Dikeos D, Djurovic S, Donnelly P, Donohoe G, Duong L, Dwyer S, Fink-Jensen A, Freedman R, Freimer NB, Friedl M, Georgieva L, Giegling I, Gill M, Glenthoj B, Godard S, Hamshere M, Hansen M, Hansen T, Hartmann AM, Henskens FA, Hougaard DM, Hultman CM, Ingason A, Jablensky AV, Jakobsen KD, Jay M, Jurgens G, Kahn RS, Keller MC, Kenis G, Kenny E, Kim Y, Kirov GK, Konnerth H, Konte B, Krabbendam L, Krasucki R, Lasseter VK, Laurent C, Lawrence J, Lencz T, Lerer FB, Liang KY, Lichtenstein P, Lieberman JA, Linszen DH, Lonnqvist J, Loughland CM, Maclean AW, Maher BS, Maier W, Mallet J, Malloy P, Mattheisen M, Mattingsdal M, McGhee KA, McGrath JJ, McIntosh A, McLean DE, McQuillin A, Melle I, Michie PT, Milanova V, Morris DW, Mors O, Mortensen PB, Moskvina V, Muglia P, Myin-Germeys I, Nertney DA, Nestadt G, Nielsen J, Nikolov I, Nordentoft M, Norton N, Nothen MM, O’Dushlaine CT, Olincy A, Olsen L, O’Neill FA, Orntoft TF, Owen MJ, Pantelis C, Papadimitriou G, Pato MT, Peltonen L, Petursson H, Pickard B, Pimm J, Pulver AE, Puri V, Quested D, Quinn EM, Rasmussen HB, Rethelyi JM, Ribble R, Rietschel M, Riley BP, Ruggeri M, Schall U, Schulze TG, Schwab SG, Scott RJ, Shi J, Sigurdsson E, Silverman JM, Spencer CC, Stefansson K, Strange A, Strengman E, Stroup TS, Suvisaari J, Terenius L, Thirumalai S, Thygesen JH, Timm S, Toncheva D, Oord van den E, Os van J, Winkel van R, Veldink J, Walsh D, Wang AG, Wiersma D, Wildenauer DB, Williams HJ, Williams NM, Wormley B, Zammit S, Sullivan PF, O’Donovan MC, Daly MJ, Gejman PV, Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium. (2011). Genome-wide association study identifies five new schizophrenia loci. Nat.Genet. 43: 969-76 [PubMed]

Stant AD, Castelein S, Bruggeman R, Busschbach van JT, Gaag van der M, Knegtering H, Wiersma D. (2011). Economic aspects of peer support groups for psychosis. Community Ment.Health J. 47: 99-105 [PubMed]

Steinberg S, Mors O, Borglum AD, Gustafsson O, Werge T, Mortensen PB, Andreassen OA, Sigurdsson E, Thorgeirsson TE, Bottcher Y, Olason P, Ophoff RA, Cichon S, Gudjonsdottir IH, Pietilainen OP, Nyegaard M, Tuulio-Henriksson A, Ingason A, Hansen T, Athanasiu L, Suvisaari J, Lonnqvist J, Paunio T, Hartmann A, Jurgens G, Nordentoft M, Hougaard D, Norgaard-Pedersen B, Breuer R, Moller HJ, Giegling I, Glenthoj B, Rasmussen HB, Mattheisen M, Bitter I, Rethelyi JM, Sigmundsson T, Fossdal R, Thorsteinsdottir U, Ruggeri M, Tosato S, Strengman E, Genetic Risk and Outcome in Psychosis (GROUP) Investigators (Kahn,R.S., Cahn W, Linszen DH, Haan de L, Os van J, Krabbendam L, Myin-Germeys I, Wiersma D, Bruggeman R), Kiemeney LA, Melle I, Djurovic S, Abramova L, Kaleda V, Walshe M, Bramon E, Vassos E, Li T, Fraser G, Walker N, Toulopoulou T, Yoon J, Freimer NB, Cantor RM, Murray R, Kong A, Golimbet V, Jonsson EG, Terenius L, Agartz I, Petursson H, Nothen MM, Rietschel M, Peltonen L, Rujescu D, Collier DA, Stefansson H, St.Clair D, Stefansson K. (2011). Expanding the range of ZNF804A variants conferring risk of psychosis. Mol.Psychiatry. 16: 59-66 [PubMed]

Swart M, Bruggeman R, Laroi F, Alizadeh BZ, Kema I, Kortekaas R, Wiersma D, Aleman A. (2011). COMT Val158Met polymorphism, verbalizing of emotion and activation of affective brain systems. Neuroimage. 55: 338-44 [PubMed]

Vehof J, Al Hadithy AF, Burger H, Snieder H, Risselada AJ, Wilffert B, Cohen D, Arends J, Wiersma D, Mulder H, Bruggeman R. (2011). Association between the ROBO1 gene and body mass index in patients using antipsychotics. Psychiatr.Genet. 21: 202-7 [PubMed]

Vehof J, Risselada AJ, Al Hadithy AF, Burger H, Snieder H, Wilffert B, Arends J, Wunderink L, Knegtering H, Wiersma D, Cohen D, Mulder H, Bruggeman R. (2011). Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication. Psychopharmacology. 216: 257-65 [Volledige tekst]

Vercammen A, Knegtering H, Bruggeman R, Aleman A. (2011). Subjective loudness and reality of auditory verbal hallucinations and activation of the inner speech processing network. Schizophr.Bull. 37: 1009-16 [PubMed]

Wiersma D, Slooff CJ. (2011). Epidemiologie en beloop. In: Cahn W, Krabbendam L, Myin-Germeys I, Bruggeman R, Haan de L (eds). Handboek Schizofrenie. Utrecht: De Tijdstroom

Williams HJ, Norton N, Dwyer S, Moskvina V, Nikolov I, Carroll L, Georgieva L, Williams NM, Morris DW, Quinn EM, Giegling I, Ikeda M, Wood J, Lencz T, Hultman C, Lichtenstein P, Thiselton D, Maher BS, Molecular Genetics of Schizophrenia Collaboration (MGS) International Schizophrenia Consortium (ISC), SGENE-plus, GROUP Investigators (Kahn RS, Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I), Malhotra AK, Riley B, Kendler KS, Gill M, Sullivan P, Sklar P, Purcell S, Nimgaonkar VL, Kirov G, Holmans P, Corvin A, Rujescu D, Craddock N, Owen MJ, O’Donovan MC. (2011). Fine mapping of ZNF804A and genome-wide significant evidence for its involvement in schizophrenia and bipolar disorder. Mol.Psychiatry. 16: 429-41 [PubMed]

Winkel van R, Beveren van NJ, Simons C, Genetic Risk and Outcome of Psychosis (GROUP) Investigators (Kahn,R.S., Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I). (2011). AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder. Neuropsychopharmacology. 36: 2529-37 [PubMed]

Winkel van R, Genetic Risk and Outcome of Psychosis (GROUP) Investigators (Kahn,R.S., Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I). (2011). Family-Based Analysis of Genetic Variation Underlying Psychosis-Inducing Effects of Cannabis: Sibling Analysis and Proband Follow-up. Arch.Gen.Psychiatry. 68: 148-57 [PubMed]

Castelein S, Bruggeman R, Busschbach van JT, Gaag van der M, Stant D, Knegtering H, Wiersma D. (2010). Lotgenotengroepen voor mensen met een psychose verbeteren kwaliteit van leven. Ned Tijdschr Geneeskd. 154: A1768

Castelein S, Bruggeman R, Busschbach van JT, Knegtering H, Gaag van der M, Wiersma D. (2010). Predictors of successful participation in peer support groups for psychosis. Schizophr.Res. 117: 276-7

Castelein S, Gaag van der M, Bruggeman R, Knegtering H. (2010). The effectiveness of peer support groups and the involvement of peer providers in multidisciplinary teams. Early Intervention in Psychosis. 4, suppl. 1: 183

Castelein S, Mulder PJ, Bruggeman R, Knegtering H. (2010). Lotgenotengroepen voor mensen met schizofrenie. In: Rooijen Sv, Weeghel Jv (eds). Jaarboek Psychiatrische Rehabilitatie. Amsterdam: SWP

Hoorn van der A, Oldehinkel AJ, Ormel J, Bruggeman R, Uiterwaal CS. (2010). Non-right-handedness and mental health problems among adolescents from the general population: The Trails Study. Laterality. 15: 304-16 [PubMed]

Knegtering H, Nienhuis FJ. (2010). Differentiaal diagnostiek van psychotische stoornissen. In: Cahn W, Krabbendam L, Myin-Germeys I, Bruggeman R, Haan de L (eds). Handboek Schizofrenie. Utrecht: De Tijdstroom

Mulder CL, Gaag van der M, Bruggeman R, Cahn W, Delespaul PA, Dries P, Faber G, Haan de L, Heijden van der FM, Kempen RW, Mogendorff ES, Slooff CJ, Sytema S, Wiersma D, Wunderink L, Os van J. (2010). Routine Outcome Monitoring for patients with severe mental illness: a consensus document. Tijdschr.Psychiatr. 52: 169-79 [PubMed]

Nienhuis FJ, Knegtering H. (2010). Classificatie en diagnostiek van psychotische stoornissen. In: Cahn W, Krabbendam L, Myin-Germeys I, Bruggeman R, Haan de L (eds). Handboek Schizofrenie. Utrecht: De Tijdstroom

Al Hadithy AF, Ivanova SA, Pechlivanoglou P, Semke A, Fedorenko O, Kornetova E, Ryadovaya L, Brouwers JR, Wilffert B, Bruggeman R, Loonen AJ. (2009). Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia. Prog.Neuropsychopharmacol.Biol.Psychiatry. 33: 475-81 [PubMed]

Al Hadithy AF, Wilffert B, Bruggeman R, Stewart RE, Brouwers JR, Matroos GE, Hoek HW, Harten van PN. (2009). Lack of association between antipsychotic-induced Parkinsonism or its subsymptoms and rs4606 SNP of RGS2 gene in African-Caribbeans and the possible role of the medication: the Curacao extrapyramidal syndromes study X. Hum.Psychopharmacol. 24: 123-8 [PubMed]

Rujescu D, Ingason A, Cichon S, Pietilainen OP, Barnes MR, Toulopoulou T, Picchioni M, Vassos E, Ettinger U, Bramon E, Murray R, Ruggeri M, Tosato S, Bonetto C, Steinberg S, Sigurdsson E, Sigmundsson T, Petursson H, Gylfason A, Olason PI, Hardarsson G, Jonsdottir GA, Gustafsson O, Fossdal R, Giegling I, Moller HJ, Hartmann A, Hoffmann P, Crombie C, Fraser G, Walker N, Lonnqvist J, Suvisaari J, Tuulio-Henriksson A, Andreassen OA, Djurovic S, Hansen T, Werge T, Melle I, Kiemeney LA, Franke B, Buizer-Voskamp JE, GROUP Investigators: ( Kahn RS, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germys I), Ophoff RA, Rietschel M, Nothen MM, Stefansson K, Peltonen L, St.Clair D, Stefansson H, Collier DA. (2009). Disruption of the neurexin 1 gene is associated with schizophrenia. Hum.Mol.Genet. 18: 988-96 [PubMed]

Schorr SG, Slooff CJ, Bruggeman R, Taxis K. (2009). Prevalence of metabolic syndrome in patients with psychotic disorders in the Netherlands. J.Clin.Psychopharmacol. 29: 399-402 [PubMed]

Schorr SG, Slooff CJ, Bruggeman R, Taxis K. (2009). The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one year. J.Psychiatr.Res. 43: 1106-11 [PubMed]

Schothorts PF, Engeland van H, Gaag van der RJ, Minderaa RB, Stockmann APAM, Westerman GMA. (2009). Richtlijn diagnostiek en behandeling autismespectrum stoornissen bij kinderen en jeugdigen. In: Anonymous Utrecht: NVvP/De Tijdstroom

Smid HG, Westenbroek JM, Bruggeman R, Knegtering H, Bosch van den RJ. (2009). Abnormal externally guided movement preparation in recent-onset schizophrenia is associated with impaired selective attention to external input. Psychiatry Res. 170: 75-81 [PubMed]

Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, Werge T, Pietilainen OP, Mors O, Mortensen PB, Sigurdsson E, Gustafsson O, Nyegaard M, Tuulio-Henriksson A, Ingason A, Hansen T, Suvisaari J, Lonnqvist J, Paunio T, Borglum AD, Hartmann A, Fink-Jensen A, Nordentoft M, Hougaard D, Norgaard-Pedersen B, Bottcher Y, Olesen J, Breuer R, Moller HJ, Giegling I, Rasmussen HB, Timm S, Mattheisen M, Bitter I, Rethelyi JM, Magnusdottir BB, Sigmundsson T, Olason P, Masson G, Gulcher JR, Haraldsson M, Fossdal R, Thorgeirsson TE, Thorsteinsdottir U, Ruggeri M, Tosato S, Franke B, Strengman E, Kiemeney LA, Genetic Risk and Outcome in Psychosis (GROUP) Consortium: (, Kahn RS, Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germys I), Melle I, Djurovic S, Abramova L, Kaleda V, Sanjuan J, Frutos de R, Bramon E, Vassos E, Fraser G, Ettinger U, Picchioni M, Walker N, Toulopoulou T, Need AC, Ge D, Yoon JL, Shianna KV, Freimer NB, Cantor RM, Murray R, Kong A, Golimbet V, Carracedo A, Arango C, Costas J, Jonsson EG, Terenius L, Agartz I, Petursson H, Nothen MM, Rietschel M, Matthews PM, Muglia P, Peltonen L, St CD, Goldstein DB, Stefansson K, Collier DA. (2009). Common variants conferring risk of schizophrenia. Nature. 460: 744-7 [PubMed]

Vercammen A, Knegtering H, Bruggeman R, Aleman A. (2009). Perceptual characteristics of auditory-verbal hallucinations are associated with activation of the inner speech processing network. In: Vercammen A (ed). Cognitive and neural processes of auditory-verbal hallucinations in schizophrenia [PhD Thesis]. Groningen: Rijksuniversiteit Groningen [Proefschrift]

Vercammen A, Knegtering H, Bruggeman R, Westenbroek HM, Jenner JA, Slooff CJ, Wunderink L, Aleman A. (2009). Effects of bilateral repetitive transcranial magnetic stimulation on treatment resistant auditory-verbal hallucinations in schizophrenia: A randomized controlled trial. Schizophr.Res. 114: 172-9 [PubMed]

Wilffert B, Al Hadithy AF, Sing VJ, Matroos G, Hoek HW, Os van J, Bruggeman R, Brouwers JR, Harten van PN. (2009). The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment: Curacao extrapyramidal syndromes study IX. J.Psychopharmacol. 23: 652-9 [PubMed]

Al Hadithy AF, Wilffert B, Bruggeman R, Brouwers JR. (2008). The impact of MDR1 polymorphisms on prolactin concentrations in patients treated with risperidone. Prog.Neuropsychopharmacol.Biol.Psychiatry. 32: 593-4 [PubMed]

Al Hadithy AF, Wilffert B, Stewart RE, Looman NM, Bruggeman R, Brouwers JR, Matroos GE, Os van J, Hoek HW, Harten van PN. (2008). Pharmacogenetics of parkinsonism, rigidity, rest tremor, and bradykinesia in African-Caribbean inpatients: differences in association with dopamine and serotonin receptors. Am.J Med.Genet.B Neuropsychiatr.Genet. 147B: 890-7 [PubMed]

Al Hadithy AFY, Ivanova SA, Pechlivanoglou P, Semke A, Fedorenko O, Kornetova E, Ryadovaya L, Brouwers JRBJ, Bruggeman R, Loonen AJM. (2008). Tardive dyskinesia and polymorphism of dopamine D3, serotonin 2A and 2C receptors in Russian psychiatric inpatients. Eur.Neuropsychopharmacol. 18: S429 [PubMed]

Al Hadithy AFY, Wilffert B, Stewart RE, Bruggeman R, Brouwers JRBJ, Matroos GE, Hoek HW, Harten van PN. (2008). No association between rs4606 SNP of the RGS2 gene and antipsychotic-induced parkinsonism, tremor, bradykinesia, and rigidity in Afro-Caribbean inpatients. Br.J.Clin.Pharmacol. 66: 732-

Cahn W, Ramlal D, Bruggeman R, Haan de L, Scheepers FE, Soest van MM, Assies J, Slooff CJ. (2008). Preventie en behandeling van somatische complicaties bij antipsychoticagebruik. Tijdschr Psychiatr. 50: 579-91

Castelein S, Bruggeman R, Busschbach van JT, Gaag van der M, Stant AD, Knegtering H, Wiersma D. (2008). The effectiveness of peer support groups in psychosis: a randomized controlled trial. Acta Psychiatr.Scand. 118: 64-72 [PubMed]

Castelein S, Gaag van der M, Bruggeman R, Busschbach van JT, Wiersma D. (2008). Measuring empowerment among people with psychotic disorders: a comparison of three instruments. Psychiatr.Serv. 59: 1338-42 [PubMed]

Castelein S, Mulder PJ, Bruggeman R. (2008). Guided peer support groups for schizophrenia: a nursing intervention. Psychiatr.Serv. 59: 326 [PubMed]

European Network of Schizophrenia Networks for the Study of Gene-Environment Interactions: Leboyer,M., Meyer-Lindenberg A, Stefanis N, Rutten BP, Arango C, Jones P, Kapur S, Lewis S, Murray R, Owen MJ, Linszen D, Kahn R, Os van J, Wiersma D, Bruggeman R, Cahn W, Germeys I, Haan de L, Krabbendam L. (2008). Schizophrenia aetiology: do gene-environment interactions hold the key? (Comment on Tandon et al. Schizophrenia Research 2008, vol 102, 1-18). [*Marion Leboyer, Andreas Meyer-Lindenberg, Nikos Stefanis, GROUP (Don Linszen, Rene Kahn, Jim van Os, Durk Wiersma and Richard Bruggeman, Wiepke Cahn, Inez Germeys, Lieuwe de Haan, Lydia Krabbendam), Bart P.F. Rutten, Celso Arango, Peter Jones, Shitij Kapur, Shôn Lewis, Robin Murray and Michael J. Owen]. Schizophr.Res. 102: 21-6 [PubMed]

Knegtering H, Bosch van den RJ, Castelein S, Bruggeman R, Os van J. (2008). Are sexual side effects of prolactin-raising antipsychotics reducible to serum prolactin? Psychoneuroendocrinology. 33: 711-7 [PubMed]

Knegtering H, Bruggeman R. (2008). Het meten van effecten van behandeling [Evaluation of treatment effects]. In: Verkes RJ, Bruggeman R (eds). Keuzecriteria voor antipsychotica. Alphen a/d Rijn: Van Zuiden Communications BV

Knegtering H, Bruggeman R. (2008). Farmacotherapie van psychosen, een handleiding voor de praktijk [Pharmacotherapy of psychotic disorders, a guideline for daily practice]. In: Verkes RJ, Bruggeman R (eds). Keuzecriteria voor antipsychotica. Alphen a/d Rijn: Van Zuiden Communications BV

Knegtering H, Bruggeman R, Verkes RJ. (2008). Naar een balans tussen gewenste en ongewenste effecten van antipsychotica [Toward a balance between desired and undesired treatment effects of antipsychotics]. In: Verkes RJ, Bruggeman R (eds). Keuzecriteria voor antipsychotica. Alphen a/d Rijn: Van Zuiden Communications BV

Schorr S, Slooff CJ, Bruggeman R, Taxis K. (2008). The incidence of metabolic syndrome and its reversibility in patients with psychotic disorders followed for one year. Eur.Neuropsychopharmacol. 18: 435-6

Schorr SG, Slooff CJ, Postema R, Oven van W, Schilthuis M, Bruggeman R, Taxis K. (2008). A 12-month follow-up study of treating overweight schizophrenic patients with aripiprazole. Acta Psychiatr.Scand. 118: 246-50 [PubMed]

Slotema CW, Harten van PN, Bruggeman R, Hoek HW. (2008). Botulinum toxin in the treatment of orofacial tardive dyskinesia: A single blind study. Prog.Neuropsychopharmacol.Biol.Psychiatry. 32: 507-9 [PubMed]

Stefansson H, Rujescu D, Cichon S, Pietilainen OP, Ingason A, Steinberg S, Fossdal R, Sigurdsson E, Sigmundsson T, Buizer-Voskamp JE, Hansen T, Jakobsen KD, Muglia P, Francks C, Matthews PM, Gylfason A, Halldorsson BV, Gudbjartsson D, Thorgeirsson TE, Sigurdsson A, Jonasdottir A, Jonasdottir A, Bjornsson A, Mattiasdottir S, Blondal T, Haraldsson M, Magnusdottir BB, Giegling I, Moller HJ, Hartmann A, Shianna KV, Ge D, Need AC, Crombie C, Fraser G, Walker N, Lonnqvist J, Suvisaari J, Tuulio-Henriksson A, Paunio T, Toulopoulou T, Bramon E, Di Forti M, Murray R, Ruggeri M, Vassos E, Tosato S, Walshe M, Li T, Vasilescu C, Muhleisen TW, Wang AG, Ullum H, Djurovic S, Melle I, Olesen J, Kiemeney LA, Franke B, GROUP Investigators: ( Kahn RS, Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germys I), Sabatti C, Freimer NB, Gulcher JR, Thorsteinsdottir U, Kong A, Andreassen OA, Ophoff RA, Georgi A, Rietschel M, Werge T, Petursson H, Goldstein DB, Nothen MM, Peltonen L, Collier DA, St.Clair D, Stefansson K. (2008). Large recurrent microdeletions associated with schizophrenia. Nature. 455: 232-6 [PubMed]

Vehof J, Postma MJ, Bruggeman R, Berg den LTWD, Berg van den PD, Stolk RP, Burger H. (2008). Predictors for Starting Depot Administration of Risperidone in Chronic Users of Antipsychotics. J.Clin.Psychopharmacol. 28: 625-30 [PubMed]

Vrijenhoek T, Buizer-Voskamp JE, Stelt van der I, Strengman E, Genetic Risk and Outcome in Psychosis (GROUP) Consortium (, Kahn,R,S, Linszen DH, Os van J, Wiersma D, Bruggeman R, Cahn W, Haan de L, Krabbendam L, Myin-Germeys I), Sabatti C, Geurts van KA, Brunner HG, Ophoff RA, Veltman JA. (2008). Recurrent CNVs disrupt three candidate genes in schizophrenia patients. Am.J.Hum.Genet. 83: 504-10 [PubMed]

Bruggeman R, Slooff CJ, Taxis K, Knegtering H, Delespaul P, The Phamous-Workgroup. (2007). De Pharmacotherapy Monitoring and Outcome Survey: Phamous, opzet en eerste resutaten [Pharmacotherapy Monitoring and Outcome Survey: PHAMOUS, design and first results]. 35e Voorjaarscongres van de Nederlandse Vereniging voor Psychiatrie, Maastricht 12 april 2007. Samenvattingenboek: 107-10

Knegtering H, Bruggeman R. (2007). What are the effects of antipsychotics on sexual functioning? Prim Psychiatry. 14: 51-6

Knegtering H, Bruggeman R. (2007). Sexual dysfunction and antipsychotics – how to bring up the issue when talking to your patients. Advances in Schizophrenia and Clinical Psychiatry. 3: 8-12

Knegtering H, Bruggeman R, Castelein S, Wiersma D. (2007). Antipsychotica en seksueel functioneren bij mensen met psychosen [ntipsychotics and sexual functioning in persons with psychoses]. Tijdschr Psychiatr. 49: 733-42 [PubMed]

Schorr SG, Slooff CJ, Postema R, Schilthuis M, Bruggeman R, Taxis K. (2007). Is switching to aripiprazole an option in overweight patients? A 12 months naturalistic follow-up study. Eur.Neuropsychopharmacol. 17: 465- [ScienceDirect]

Bruggeman R, Knegtering H. (2006). Specialistische behandelmethoden bij gehoorshallucinaties. Medicamentueze behandeling van hallucinaties. In: Jenner JA (ed). Hallucinaties: kenmerken, verklaringen en behandeling. Assen: Van Gorcum

Bruggeman R, Laar van T, Knegtering H. (2006). Verklaringsmodellen voor hallucinaties. De rol van neurotransmitters bij het ontstaan van hallucinaties. In: Jenner JA (ed). Hallucinaties: kenmerken, verklaringen en behandeling. Assen: Van Gorcum

Castelein S, Bruggeman R, Busschbach van JT, Gaag van der M, Knegtering R, Wiersma D. (2006). The effectiveness of ‘professionally guided’ self-help groups: A multicenter randomized controlled trial. Schizophr.Res. 86: s56

Castelein S, Bruggeman R, Busschbach van JT, Wiersma D. (2006). Begeleide lotgenotengroepen voor mensen met een psychose. Een gecontroleerde effectiviteitsstudie. Groningen: Rob Giel Onderzoekcentrum/UMCG. Verschenen als deel 10 in de RGOc-reeks

Castelein S, Mulder PJ, Bruggeman R. (2006). Draaiboek voor het begeleiden van een lotgenotengroep voor mensen met een psychose. Groningen: Rob Giel Onderzoekcentrum. Verschenen als deel 11 in de RGOc-reeks

Kemperman RFJ, Veurink M, Wal van der T, Knegtering H, Bruggeman R, Fokkema MR, Kema IP, Korf J, Muskiet FA. (2006). Low essential fatty acid and B-vitamin status in a subgroup of patients with schizophrenia and its response to dietary supplementation. Prostaglandins Leukot.Essent.Fatty Acids. 74: 75-85 [PubMed]

Zempleni MZ, Bruggeman R, Knegtering H, Bosch van den RJ, Stowe L. (2006). Comprehension of idiomatic and non-idiomatic sentences in schizophrenia: results of a pilot fMRI study. In: Zempleni MZ (ed). Functional imaging of the hemispheric contribution to language processing. PhD Thesis. Groningen: University of Groningen

Castelein S, Bruggeman R. (2005). Lotgenotencontact. In: Anonymous Multidisciplinaire richtlijn Schizofrenie 2005. Richtlijn voor de diagnostiek, zorgorganisatie en behandeling van volwassen cliënten met schizofrenie. Landelijke Stuurgroep Multidisciplinaire Richtlijnontwikkeling in de GGZ (onder auspiciën van). Utrecht: Trimbos-instituut

Castelein S, Bruggeman R, Busschbach van JT, Gaag van der M, Mulder PJ, Knegtering H, Wiersma D. (2005). The effectiveness of support groups for people suffering from psychosis: A multi-center randomized controlled trial. Schizophr.Bull. 31: s521-2

Castelein S, Mulder PJ, Bruggeman R. (2005). Lotgenoten. In: Anonymous Zorg rondom Schizofrenie. Bohn Stafleu van Loghum

Kemperman RFJ, Veurink M, Wal van der T, Knegtering H, Bruggeman R, Fokkema MR, Kema IP, Korf J, Muskiet FA. (2005). Essential fatty acid and b-vitamin status in schizophrenia. Schizophr.Bull. 31: 251

Knegtering H, Bruggeman R. (2005). Meetinstrumenten bij psychotische stoornissen. In: Wunderink A (ed). Schizofrenie deel 2, diagnostiek en behandeling. Leusden: Mark Two Communications BV

Knegtering H, Bruggeman R, Castelein S. (2005). Antipsychotica en seksueel functioneren bij mensen met psychotische stoornissen [ntipsychotics and sexual functioning in people with psychosis]. In: Slooff CJ, Withaar F, Gaag van der M (eds). Terugvalpreventie bij schizofrenie en verwante psychosen [Relapse prevention in schizophrenia and related psychosis]. Den Haag: Kenniscentrum Schizofrenie Nederland

Knegtering R, Baselmans P, Castelein S, Bosker F, Bruggeman R, Bosch van den RJ. (2005). Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am.J.Psychiatry. 162: 1010-2 [PubMed]

Rijcken CA, Knegtering H, Bruggeman R, Tobi H, Jong de-Berg van den LT. (2005). Sex differences in concomitant medication with benzodiazepines or antidepressants in first-break schizophrenic patients treated with antipsychotic medication. Psychiatry Res. 134: 143-50 [PubMed]

Smid HGOM, Bruggeman R, Knegtering H, Burgel van J, Bosch van den RJ. (2005). Schizophrenia symptoms, schizotypy, vulnerability factors and cognitive efficacy in first onset schizophrenia patients and healthy controls. Schizophr.Bull. 31: 377

Bruggeman R, Kamphuis JR, Castelein S, Knegtering H. (2004). Do atypical antipsychotics differentially affect bone mineral density? Schizophr.Res. 67: s18

Knegtering H, Bosveld-van Haandel LJM, Kluiter H, Bruggeman R, Castelein S, Bosch van den RJ. (2004). Is the niacin skin flushing test a tool in the diagnosis of schizophrenia? Schizophr.Res. 67: s120

Knegtering H, Castelein S, Bous J, Linde van der J, Bruggeman R, Kluiter H, Bosch van den RJ. (2004). A randomized open-label trial of the impact of quetiapine versus risperidone on sexual functioning. J.Clin.Psychopharmacol. 24: 56-61 [PubMed]

Knegtering H, Castelein S, Bruggeman R. (2004). Schizofrenie, seksueel functioneren en behandeling met antipsychotica. Magazine Psychose & Zorg. zomer: 8-10

Knegtering H, Castelein S, Bruggeman R. (2004). Vaak seksuele functiestoornissen door antipsychotica, vooral bij prolactineverhoging: resultaten van een aantal vergelijkende onderzoeken [Frequent sexual dysfunctions as side-effects of antipsychotic medication, especially those associated with increased prolactin levels: The results of several comparative studies]. Tijdschr Seksuologie. 28: 140-7

Knegtering H, Bruggeman R. (2003). Welk (depot) neurolepticum is een goede keus bij een chronisch psychotische patiënt met epilepsie die fenytoine en carbamazepine gebruikt? (Which antipsychotic medication is a good choice in patients with a chronic psychotic illness and epilepsy being treated with fenytoine and carbamazepine?). Apothekers Vademecum. 3

Knegtering H, Slooff CJ, Bruggeman R, Arends J, Withaar F, Wolff H. (2003). Behandelprotocollen bij schizofrenie en verwante psychosen. Deel 1. Assen: Koninklijke van Gorcum